L-β-galactoglucan produced from agrobacterium, preparation method for l-β-galactoglucan, and use of l-β-galactoglucan

Abstract

The present invention provides L-β-galactoglucan, a preparation method therefor, and a use thereof. The polysaccharide is sinistrin, is composed of β-D-glucose and β-D-galactose, and has a molecular weight of not less than 5000 Da. The preparation method for the polysaccharide comprises: inoculating Agrobacterium FN01 in a culture solution for fermentation to obtain a fermentation broth; mixing the fermentation broth with alcohol, and carrying out precipitation and drying to obtain a crude polysaccharide product; and then carrying out purification to obtain a purified polysaccharide product, or carrying out enzymolysis on the fermentation broth by using glucanase, and then carrying out filtration, ultrafiltration concentration, and spray-drying to obtain a purified polysaccharide product. The polysaccharide has the effects of treating and / or preventing liver injury, resisting aging, decreasing blood sugar, repairing tissues and the like, and is a multipurpose polysaccharide.

Description

L-β-galactoglucan produced by Agrobacterium and its preparation method and application Cross-references This application claims the priority of Chinese patent application CN2023107516693, filed on June 25, 2023. This application cites the full text of the above Chinese patent application. Technical Field The invention relates to the technical field of polysaccharides in microbiology, and in particular to L-β-galactoglucan produced by Agrobacterium FN01 and a preparation method and application thereof. Background Art Agrobacterium is a Gram-negative, aerobic, non-spore-forming rod-shaped bacterium belonging to the Rhizobium family, but it does not fix nitrogen. Some are peritrichous and some are monotrichous. They are distributed in the soil, and most of them can cause carcinogenesis in plants. Polysaccharides are high-molecular carbohydrates composed of sugar chains linked by glycosidic bonds, consisting of at least 10 monosaccharides. They are widely present in animal cell membranes and the cell walls of plants and microorganisms. They not only exert multiple biological activities in various organisms, but also have multiple functions in the process of mutual influence between various organisms. They are highly effective biological response regulators. Polysaccharides generally have multiple activities, such as multi-immune regulation, anti-tumor, hypoglycemic, lipid-lowering, etc., which have attracted great attention from the medical community at home and abroad and have become a hot spot for research and application in recent years. However, the structure of polysaccharide compounds is extremely complex, which also leads to the complexity of the physicochemical properties and physiological activities of polysaccharides, which are mainly reflected in the following aspects: (1) Monosaccharide composition and arrangement: Polysaccharides are composed of multiple monosaccharide units, which can be completely identical (called homopolysaccharides) or different (called heteropolysaccharides). The type of monosaccharides (such as glucose, fructose, galactose, etc.) and the order in which they are arranged will affect the structure and properties of polysaccharides. (2) Glycosidic bond type: The monosaccharide units in polysaccharides are linked together by glycosidic bonds. The type of glycosidic bond (e.g., α-1,4, β-1,4, etc.) and the mode of connection (e.g., linear, branched, etc.) have an important influence on the structure and properties of polysaccharides. (3) Substituents and modifications: Polysaccharide molecules may carry various substituents (such as sulfate, acetyl, etc.) and modifications (such as phosphorylation, sulfation, etc.), which further increase the complexity of the polysaccharide structure. (4) The three-dimensional structure of polysaccharides can be divided into linear structure, branched structure, helical structure, etc. When the three-dimensional structure of polysaccharides is different, their physical and chemical properties and biological activities will also be different. This is because different three-dimensional structures will affect the spatial conformation of polysaccharides and the interaction between molecules, thereby affecting their solubility, stability, biological activity and other aspects. Since the properties of polysaccharides are largely determined by their structure, even if only one monosaccharide unit is different, the physicochemical properties of the polysaccharide may change significantly. Such changes may be reflected in solubility, viscosity, gelation, stability, etc., and may also affect the biological activity and function of the polysaccharide. For example, starch and cellulose are both polysaccharides composed of glucose units, but their structures and properties are very different. Starch has a helical structure, mainly composed of glucose units connected by α-1,4 glycosidic bonds, and is soluble, while cellulose has a linear structure, composed of glucose units connected by β-1,4 glycosidic bonds, and is insoluble and fibrous. This structural difference leads to completely different functions and effects in organisms. In addition, the three-dimensional structure of polysaccharides will also affect their interaction with other molecules. For example, some polysaccharides with specific three-dimensional structures can bind to specific proteins or cell surface receptors to exert specific biological activities. This interaction has important application value in the fields of biomedicine and drug development. Therefore, the structural complexity of polysaccharides is reflected not only in the diversity of their composition and arrangement, but also in the diversity of their substituents and modifications. This complexity gives polysaccharides a variety of different physical and chemical properties and biological activities, providing a wide range of application prospects in the fields of biomedicine, food science, etc. The use of Agrobacterium to prepare polysaccharides and determine their structure and biological activity is of great significance for the treatment of related diseases. Summary of the invention During the study of Agrobacterium FN01, it was discovered by chance that this strain could produce an extracellular polysaccharide by fermentation, which has the following activities: (1) Treat and / or prevent diseases related to glucose metabolism disorders; (2) having at least one of the effects of promoting skin repair, tissue regeneration, wound healing, and apoptotic cell clearance; (3) Enhance nonspecific immune function; (4) Treatment and / or prevention of liver-related diseases; (5) Anti-fatigue; (6) Regulate intestinal flora; (7) Anti-aging; (8) having at least one of the following effects: moisturizing, increasing skin elasticity, and whitening and removing freckles; (9) Improve the health of animals; (10) Products that inhibit Malassezia. Based on the above research, the present invention provides an L-β-galactoglucan, which is a levulose mainly composed of β-D-glucose and β-D-galactose, and has a molecular weight of not less than 5000Da. Further, in various embodiments of the present invention, the molecular weight distribution is 1×10 6 Big or above. Furthermore, in various embodiments of the present invention, the weight average molecular weight is 4.5 million to 5.5 million Da, such as 4.98 million to 5 million Da. Furthermore, the contents of β-D-glucose and β-D-galactose are 94% to 98% and 2% to 6%, respectively. Furthermore, in the infrared spectrum of the polysaccharide, at least at 3436.8 cm -1 、2887.3cm -1 、1616.0cm -1 , 1000cm -1 ~1200cm -1 、1043.5cm -1 、1073.0cm -1 、1161.0、893.0cm -1 There are characteristic peaks. Furthermore, the polysaccharide may contain one or more of the following glycosidic bonds: (1→), (1→6), (1→2), (l→2,6), (l→4), (l→4,6), (1→3), (1→3,6), (1→2,3), (l→2,4), (l→3,4), (l→2,3,4). Furthermore, the polysaccharide may contain one or more of the following glycosidic bond connection modes: ①Glcp(1→, ②→3)Galp(1→, ③→6)Galp(1→, ④→4)Galp(1→, ⑤→6)Glcp(1→, ⑥→3,6)Galp(1→, ⑦→4,6)Glcp(1→, ⑧→2,3,6)Glcp(1→ and ⑨→2,3,4,6)Glcp(1→. Based on the test results, it can be inferred that the repeating unit structure of the polysaccharide is as follows: Wherein, Glcp is pyranose glucose, Galp is pyranose galactose, and n is an integer not less than 30. The present invention provides a method for preparing the L-β-galactoglucan, comprising the following steps: (1) inoculating Agrobacterium FN01 into a culture solution for fermentation to obtain a fermentation solution; (2) The fermentation broth is precipitated with alcohol and dried to obtain a crude polysaccharide; the crude polysaccharide is dissolved, an alkali and a filter aid are added to filter, and the filtrate is precipitated with alcohol and dried to obtain a pure polysaccharide; or the fermentation broth is hydrolyzed with glucanase, filtered, concentrated by ultrafiltration, and spray-dried to obtain a pure polysaccharide. The conventional process and procedures of Agrobacterium fermentation mainly include: Prepare the culture medium: First, you need to prepare a culture medium suitable for the growth of Agrobacterium, which usually includes basic nutrients (such as carbon source, nitrogen source, inorganic salts, etc.) and growth factors. Activation and expansion of strains: Pick a small amount of bacteria from the preserved Agrobacterium strains and inoculate them on a plate containing an appropriate culture medium for activation culture. After the colonies grow, pick a single colony and inoculate it into the seed culture medium for shake flask culture to expand the amount of bacteria. Fermentation culture: The expanded cultured Agrobacterium is inoculated into the fermentation medium for fermentation culture. Fermentation conditions (such as temperature, pH value, stirring speed, ventilation volume, etc.) should be optimized according to the characteristics of the strain and product requirements. During the fermentation process, various indicators of the fermentation liquid (such as bacterial density, metabolite concentration, etc.) should be regularly tested to monitor the fermentation process. In the process of cultivating Agrobacterium, the important substances in the culture medium or culture solution are mainly the following categories: Nitrogen sources: such as peptone, yeast extract powder, etc., are the raw materials for synthesizing bacterial proteins, nucleic acids and other nitrogen compounds. Carbon source: such as sugars, glucose, sucrose, maltose, lactose, etc., is the main source of energy for fungi and also participates in the synthesis of cellular substances. Inorganic salts: such as dipotassium hydrogen phosphate, magnesium sulfate, etc., participate in the metabolic process of fungi and maintain osmotic pressure and acid-base balance. In addition, corresponding growth factors, such as vitamins and amino acids, can be added according to the characteristics and needs of specific fungi. The main functions of these nutrients are to provide the energy required for bacterial growth and reproduction, synthesize raw materials for bacteria, activate the activity of bacterial enzymes and regulate osmotic pressure. In addition to the above essential nutrients, water needs to be added to the culture medium as a solvent, and it may also be necessary to add solidifying substances such as agar as excipients. In a specific embodiment of the present invention, the culture solution may include the following components: 1.5-6.5% carbon source, 0.1-0.5% nitrogen source, 0.1-0.3% potassium dihydrogen phosphate, 0.01-0.06% magnesium sulfate, 0.001-0.003% ferrous sulfate, 0.0006-0.0012% manganese sulfate, 0.005-0.01% calcium chloride, and 0.05-0.2% defoaming agent. Furthermore, the carbon source can be selected from glucose, mannose, maltose and lactose; the nitrogen source can be selected from potassium nitrate, sodium nitrate and peptone. Wherein, the inoculation amount of the Agrobacterium FN01 is 1-10% of the culture solution. Wherein, in step (1), an acid or a base is used to adjust the pH to 6.5-7.5, and the fermentation temperature is 28-32°C. In the process of polysaccharide purification, the addition of alkali can remove impurities such as proteins. Commonly used alkalis are mainly inorganic alkalis, such as sodium hydroxide (NaOH) and potassium hydroxide. Filter aids are usually used to improve filtration efficiency and help remove suspended particles and impurities in the solution, thereby accelerating the purification process of polysaccharides. Commonly used filter aids include diatomaceous earth, perlite, cellulose, etc. They have a large specific surface area and good adsorption properties, and can effectively remove impurities in the solution. In a specific embodiment of the present invention, the alkali in step (3) includes but is not limited to sodium hydroxide, potassium hydroxide, and calcium hydroxide; and the filter aid is selected from diatomaceous earth and perlite powder. The "alcohol precipitation" described in the present invention is a method of separating the target substance from water and impurities by separating the precipitate and the solution after adding ethanol, utilizing the different solubility characteristics of the target substance in ethanol and water. The purpose of alcohol precipitation is to remove water and impurities and retain the effective components of polysaccharides. In the extraction and purification process of polysaccharides, polysaccharides are mainly soluble in water. After adding a certain amount of ethanol, the solubility of polysaccharides is reduced and thus precipitated out, and separated from water and other components. Commonly used alcohol precipitation solvents include, but are not limited to, methanol, ethanol, and isopropanol. However, generally speaking, considering safety, cost, etc., ethanol is a more commonly used alcohol precipitation solvent. In the present invention, the fermentation is aerobic fermentation, and ventilation and stirring are continuously performed during the fermentation process, the ventilation volume is 0.2-1.0 vvm, and the stirring speed is 60-150 rpm. In a specific embodiment of the present invention, 0-24h, 0.2-0.4 vvm, stirring speed is 60 rpm; 24-48h, 0.5-0.7 vvm, stirring speed is 100 rpm; 48h to the end of fermentation, 0.9-1.0 vvm, stirring speed is 150 rpm. The present invention provides use of L-β-galactoglucan, Agrobacterium fermentation broth containing L-β-galactoglucan, and crude L-β-galactoglucan polysaccharide in preparing products for treating and / or preventing diseases related to sugar metabolism disorders. The "sugar metabolism disorder" mentioned in the present invention refers to the abnormal structure, function, concentration of hormones or enzymes that regulate the metabolism of glucose, fructose, galactose, etc., or pathological and physiological changes in tissues and organs. Monitoring blood sugar will show an increase in blood sugar. Clinically important sugar metabolism disorders are mainly excessively high and low blood sugar concentrations. Common diseases related to glucose metabolism disorders include diabetes, hypoglycemia, fructose metabolism disorders, glycogen storage diseases, galactose metabolism disorders, and pyruvate metabolism disorders. Diabetes is a metabolic disorder such as increased blood sugar caused by absolute insulin deficiency and / or reduced biological effect of insulin. It can also lead to chronic complications such as vascular and neurological complications. Wherein, the product is a product for protecting pancreatic islet cells and / or lowering blood sugar. Furthermore, the pancreatic islet cells are pancreatic β cells. Pancreatic β cells (i.e. pancreatic B cells) are a type of pancreatic cells, accounting for about 60% to 80% of pancreatic cells. They can secrete insulin and play a role in regulating blood sugar together with glucagon secreted by pancreatic A cells. Protect pancreatic islet cells, including avoiding islet cell damage, or promoting islet cell repair or new islet cell proliferation after islet cell damage. Hypoglycemia refers to reducing abnormally high blood sugar levels in patients, which is often associated with diabetes. The product for treating and / or preventing diseases related to glucose metabolism disorders can lower blood sugar by inhibiting hepatic gluconeogenesis and hepatic glucose output, increasing peripheral tissue sensitivity to insulin, promoting glucose uptake and utilization, stimulating pancreatic β cells to secrete insulin, enhancing the binding effect of insulin to receptors, and increasing target cell sensitivity to insulin. The invention provides use of L-β-galactoglucan, Agrobacterium fermentation broth containing L-β-galactoglucan, and crude L-β-galactoglucan polysaccharide in preparing a product promoting skin repair. Skin repair usually refers to the process by which the skin recovers its normal structure and function through a series of physiological processes after being damaged. This includes the regeneration of the epidermis, the repair of the dermis, and the reconstruction of skin appendages. Skin repair is an important part of skin health maintenance and can effectively resist the damage of the external environment. The important processes of skin repair include, but are not limited to, at least one of tissue regeneration, wound healing, and apoptotic cell clearance. Tissue regeneration is the continuous renewal of an organism's tissues, the death of old cells and the generation of new cells; or the repair process after tissues are damaged. Wound healing refers to the process of healing and repair of skin and other tissues after they are broken or damaged by external forces. Wound healing is a complex biological process involving multiple stages such as inflammatory response, cell proliferation, and tissue remodeling. The quality of wound healing directly affects the patient's recovery speed and prognosis. Apoptotic cell clearance, a form of programmed cell death, refers to the process in which cells, after being stimulated by certain signals, initiate internal programs to self-destruct. The clearance of apoptotic cells is an important mechanism for the body to maintain tissue homeostasis and prevent the spread of inflammatory responses. The clearance of apoptotic cells is usually completed by immune cells such as macrophages, which phagocytose and digest apoptotic cells to prevent them from releasing harmful substances that damage surrounding tissues. When the skin or tissue is damaged, the body will initiate a repair mechanism to restore the normal structure and function of the tissue by promoting cell proliferation, differentiation and synthesis of extracellular matrix. In this process, the removal of apoptotic cells is also an essential part, which helps prevent the spread of inflammatory response and reduce tissue damage. The invention provides an L-β-galactoglucan, an Agrobacterium fermentation liquid containing the L-β-galactoglucan, and an L-β-galactoglucan polysaccharide crude product, and uses the L-β-galactoglucan in preparing a product for inhibiting Malassezia. In a specific embodiment of the present invention, L-β-galactoglucan can effectively inhibit the expression of the inflammatory factor IL-6 gene induced by Malassezia. Malassezia (Pityrosporum), also known as Pityrosporum, is classified as a hyphomycete in mycology and belongs to the Basidiomycetes, Basidiosporales, and Basidiosporaceae. Malassezia is a fungus that parasitizes on the surface of normal skin of humans and animals. It is mainly distributed in sebum-rich areas such as the scalp, face, chest and back, accounting for about 50% to 80% of the total fungi colonizing healthy human skin. Under normal circumstances, it does not cause disease, but under the promotion of certain factors, it can multiply in large numbers, decompose lipids, cause morphological changes in keratinocytes and cell apoptosis, and eventually cause corresponding diseases. Malassezia can cause diseases such as pityriasis versicolor, Malassezia folliculitis, and seborrheic dermatitis. Patients may experience inflammation, rosacea, fever, and other symptoms. Furthermore, in the present invention, the product for inhibiting Malassezia is a product for treating skin infections caused by Malassezia. Malassezia is a common colonizing flora on the scalp. As a conditional pathogen, it can cause a variety of superficial and deep fungal diseases under the influence of susceptibility factors. When Malassezia overgrows on the scalp, it usually causes tinea capitis and may cause symptoms such as increased dandruff, greasy hair, and itchy scalp. If there is a large number of Malassezia bacteria growing abnormally on the scalp, the following symptoms may occur: (1) Increased dandruff: The abnormal reproduction of Malassezia will destroy the normal ecological balance of the scalp, leading to the excessive production of dandruff. (2) Scalp itching: Large-scale growth of Malassezia may irritate the scalp and cause itching and discomfort. (3) Greasy hair: The growth of Malassezia may promote the secretion of scalp oil, making the hair greasy. (4) Hair loss: The massive reproduction of Malassezia may destroy the normal structure of hair follicles, thereby affecting the normal growth of hair. If the damage to the hair follicles is severe, permanent hair loss will occur. Based on the above, the Malassezia-inhibiting product of the present invention is also a product for treating Malassezia-induced scalp infections. Such a product can soothe the scalp, repair the scalp ecological balance, reduce irritation, itching and hair loss, etc. The invention provides L-β-galactoglucan, an Agrobacterium fermentation liquid containing L-β-galactoglucan, and an L-β-galactoglucan polysaccharide crude product for use in preparing an immunity-enhancing product. The immunity enhancement described in the present invention includes but is not limited to enhancing specific immunity and nonspecific immunity, especially improving nonspecific immunity. Nonspecific immunity is also known as innate immunity, which can be divided into: tissue barrier immunity (skin and mucosal system, blood-brain barrier, placental barrier, etc.); innate immune cell immunity (phagocytes, killer cells, dendritic cells, etc.), innate immune molecular immunity (complement, cytokines, enzymes, etc.). In a specific embodiment of the present invention, the enhancement of nonspecific immunity mainly includes but is not limited to increasing the number of (innate) immune cells and / or regulating the function of (innate) immune cells. Immune cells refer to cells that participate in or are related to immune responses; immune cells include lymphocytes, dendritic cells, monocytes / macrophages, granulocytes, mast cells, etc. Wherein, the product is used in a product for increasing the number of phagocytes and / or promoting phagocytosis of phagocytes. Furthermore, the phagocytes are macrophages and / or neutrophils. Phagocytes refer to a group of cells in the body that have phagocytic functions, mainly including the mononuclear phagocyte system and neutrophils. The mononuclear phagocyte system includes monocytes that are free in the blood and macrophages that develop after entering various tissues. Macrophages have strong phagocytic ability and are also a major type of antigen-presenting cells, playing a key role in the induction and regulation of specific immune responses. Neutrophils are a type of small phagocyte that has nonspecific immune defense functions and participates in the body's immune response, inflammatory damage, etc. Wherein, the product is a product for increasing the number of lymphocytes. Furthermore, the lymphocytes are T cells. Lymphocytes are a type of cell line with immune recognition function. According to their migration, surface molecules and functions, they can be divided into T lymphocytes (T cells), B lymphocytes (B cells) and natural killer (NK) cells. Both T cells and B cells are antigen-specific lymphocytes; lymphocytes are important cells that fight external infections and monitor cell mutations in the body. The present invention provides use of L-β-galactoglucan, Agrobacterium fermentation broth containing L-β-galactoglucan, and crude L-β-galactoglucan polysaccharide in products for treating and / or preventing liver damage. Liver injury refers to damage to the liver caused by one or more reasons, such as inflammation, bleeding, infection, etc. of the liver. Clinically, it can be divided into narrow liver injury and broad liver injury according to the different causes. Narrow liver injury generally refers to rupture and bleeding of the liver caused by trauma. Broad liver injury also includes various inflammatory diseases of the liver in the internal medicine system, such as drug-induced hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, various viral hepatitis, autoimmune liver disease, etc. Alcoholic liver damage: Alcoholic liver damage can be divided into three stages according to the severity of alcohol damage to the liver, namely alcoholic fatty liver, alcoholic hepatitis and alcoholic cirrhosis. Drinking a lot of alcohol for a long time will cause the fat in the liver to change, and it cannot be metabolized in the liver cells, and gradually accumulate into alcoholic fatty liver; in the process of metabolizing alcohol in the liver, the metabolites, ethanol and metabolic derivatives produced will cause an inflammatory reaction in the liver, and the inflammation will damage the liver cells and even cause necrosis, which will lead to the occurrence of alcoholic hepatitis; if the damage in the first and second stages is not controlled in time and allowed to develop, it will gradually develop into nodules, fibrosis, liver fibrosis, and finally cirrhosis. At this time, the damage to the liver is irreversible and may turn into liver cancer. Non-alcoholic liver damage: This damage may be caused by a variety of factors, such as drug-induced hepatitis, fatty liver, viral hepatitis, autoimmune liver disease, etc. These diseases may lead to liver cell degeneration, necrosis and fibrosis, and the examination results may show non-alcoholic liver damage. For example, fatty liver is mostly caused by abnormal fat metabolism, which may be asymptomatic or non-alcoholic liver damage may occur. It is necessary to pay attention to diet control, strengthen exercise, and give drug treatment when necessary. There is a close relationship between liver damage and liver transaminases (such as AST aspartate aminotransferase and ALT alanine aminotransferase). When liver cells are damaged, the transaminases in the liver cells are released into the blood, resulting in increased transaminase levels in the blood. Therefore, AST and ALT are commonly used liver function indicators to assess the degree of liver cell damage. Lowering transaminase activity can help treat liver damage to some extent: (1) Reduce liver inflammation: Elevated transaminase is a sign of liver inflammation. Reducing transaminase activity means reducing the liver's inflammatory response and helping to alleviate further damage to liver cells. (2) Repairing damaged liver cells: Some drugs or treatments can reduce transaminase activity while promoting the repair and regeneration of liver cells. This helps restore the normal function of the liver and thus improves the patient's overall health. (3) Delaying disease progression: By reducing transaminase activity, the progression of liver diseases such as cirrhosis and liver cancer can be delayed. This is of great significance for improving the quality of life of patients and prolonging their survival. Based on the importance of transaminase in liver damage, the present invention also provides a product that reduces AST and / or ALT activity. Wherein, the product is a product for protecting liver tissue. The invention provides use of L-β-galactoglucan, Agrobacterium fermentation liquid containing L-β-galactoglucan, and crude L-β-galactoglucan polysaccharide in preparing anti-fatigue products. Fatigue is a subjective feeling of tiredness and weakness, but objectively it will cause the loss of ability to complete normal activities or work under the same conditions. Feeling tired is not a specific symptom. Many diseases can cause fatigue, accompanied by a variety of neurological and psychiatric symptoms, but there is no organic or psychiatric disease. Reactive oxygen species (ROS): ROS are a class of highly reactive molecules produced during cellular metabolism, including peroxides, superoxides, hydroxyl radicals, singlet oxygen, and α-oxygenase. ROS are formed as a natural byproduct of the normal metabolism of oxygen and play an important role in cell signaling and homeostasis. In a state of fatigue, the production of ROS may increase, leading to elevated levels of oxidative stress within cells. This state of oxidative stress may cause damage to cellular structure and function, further exacerbating the feeling of fatigue. The accumulation of ROS has been associated with a variety of fatigue-related diseases and pathological conditions, including cardiovascular disease, diabetes, and neurodegenerative diseases. ATP (adenosine triphosphate): ATP is the main energy molecule in cells. It is composed of adenine, ribose and three phosphate groups. It releases more energy when hydrolyzed. It is the most direct source of energy in organisms and is essential for maintaining normal cell function and metabolism. In a state of fatigue, ATP production may decrease, while consumption may increase. This state of insufficient energy supply will lead to decreased cell function and further aggravate fatigue. A decrease in ATP levels is associated with a variety of fatigue-related symptoms, such as muscle fatigue, lack of concentration and memory loss. Lactic acid metabolism: Lactic acid is a metabolite produced when muscles undergo anaerobic metabolism under hypoxic conditions. After strenuous or prolonged exercise, muscle tissue may undergo anaerobic metabolism due to insufficient oxygen supply, producing a large amount of lactic acid. The accumulation of lactic acid can cause local muscle soreness and fatigue, affecting exercise ability and recovery speed. In addition, the accumulation of lactic acid may also cause an imbalance in the body's acid-base balance, further exacerbating fatigue. ROS, ATP and lactate metabolism all play an important role in fatigue. By regulating the levels of these factors, fatigue can be effectively alleviated and the body's adaptability and recovery speed can be improved. The present invention provides applications of L-β-galactoglucan, Agrobacterium fermentation broth containing L-β-galactoglucan, and crude L-β-galactoglucan polysaccharide in preparing products for regulating intestinal flora. Intestinal flora refers to the bacterial flora that grows in the intestines of humans and animals and is interdependent with humans and animals for a long time. The importance of intestinal flora in organisms is mainly reflected in the following aspects: (1) Aid digestion: Intestinal flora can break down and digest certain components in food, such as cellulose, protein, carbohydrates, etc., and promote the absorption and utilization of nutrients. (2) Maintaining intestinal health: Intestinal flora can inhibit the growth of harmful bacteria, maintain the microecological balance of the intestine, and help prevent intestinal infections and diseases. At the same time, intestinal flora, as antigens, can stimulate and promote the development and functional maturation of the immune system and enhance the body's immunity. (3) Promote nutrient absorption: Intestinal flora can secrete a variety of enzymes, which help promote the absorption and utilization of nutrients, such as vitamins and amino acids. The benefits of regulating intestinal flora to humans and animals are mainly reflected in improving intestinal health, enhancing immunity, promoting nutrient absorption, and preventing diseases. For example, the balance of intestinal flora can be adjusted through dietary adjustments and probiotic supplementation, thereby improving diarrhea, enhancing the body's resistance, promoting the absorption and utilization of nutrients, and preventing the occurrence of intestinal diseases and tumors. In animals, regulating intestinal flora can also help improve animal growth performance and enhance disease resistance. The product for regulating intestinal flora of the present invention, in a specific embodiment, is a product for promoting the proliferation of intestinal probiotics and promoting intestinal health. Wherein, the product is a product for increasing the number of Lactobacillus brevis in the intestine. The present invention provides use of L-β-galactoglucan, Agrobacterium fermentation liquid containing L-β-galactoglucan, and crude L-β-galactoglucan polysaccharide in preparing anti-aging products. Aging refers to the phenomenon that the body's physiological and psychological adaptability to the environment is progressively reduced and gradually tends to death. Aging can be divided into physiological aging and pathological aging. The former refers to the physiological degeneration process that occurs after maturity, while the latter refers to the senile changes caused by various external factors (including various diseases). Aging is the inevitable result of the combined effects of many pathological, physiological and psychological processes. It is a biological and psychological process in the final stage of individual growth and development. Anti-aging refers to the use of various methods to delay the functional decline of various body systems in order to maintain health and prolong life. Anti-aging aims to prevent or slow down physiological changes associated with aging, such as accumulation of cell damage and dysregulated gene expression. These changes may lead to problems such as decreased organ function and reduced metabolic rate. In aging cells, β-galactosidase not only accumulates in large quantities, but also lysosomes swell and the optimal pH shifts to 6.0. Its activity increases significantly and it is also one of the most widely used markers of cell aging. Telomeres are special structures at the ends of chromosomes, and their length gradually shortens as cells divide. Telomerase is an enzyme that can repair and extend the length of telomeres. In youth, telomerase activity is high, which can maintain the stability of telomeres, thereby maintaining the health and vitality of cells. However, with age, telomerase activity gradually decreases, and telomere length continues to shorten, eventually leading to cell aging and a decline in body function. Therefore, by increasing the activity of telomerase, telomere length can be extended, cell aging can be reversed, and the body's circulation can be restored. It can maintain vascular elasticity and cell activity, thereby delaying the process of cell aging. The anti-aging method of the present invention includes inhibiting the activity of β-galactosidase and / or increasing the activity of telomerase. The present invention provides an application of L-β-galactoglucan, an Agrobacterium fermentation broth containing L-β-galactoglucan, and a crude L-β-galactoglucan polysaccharide in the preparation of a product having at least one of the functions of moisturizing, increasing skin elasticity, and inhibiting melanin, including but not limited to skin care products. By detecting the relative expression of genes related to skin elasticity (skin collagen col1a1a, col1a1b, col1a2 genes), it can be shown whether the sample has the effect of increasing skin elasticity. Studies have shown that when using products that promote skin elasticity, the relative expression of col1a1a, col1a1b, col1a2 genes is significantly increased compared to the normal group. The product described in the present invention is a product for upregulating the relative expression levels of col1a1a and col1a1b genes. Hydrating and moisturizing can maintain skin moisture balance, improve dryness and roughness, reduce fine lines, enhance skin radiance, relieve tightness, etc. Melanin is a dark brown pigment found in animals and plants. It is produced and stored in a special cell, the melanocyte (also known as the melanin matrix). It is because of the existence of melanin that the skin has color. The production of melanin is mostly related to endocrine disorders and sunlight exposure. The number of melanocytes mainly depends on genetics. In addition, it is also related to endocrine hormones and nutritional status. Diseases caused by melanin include freckles, chloasma, melanosis, etc. Inhibiting the production of melanin can achieve whitening and freckle removal effects to a certain extent. The present invention provides use of L-β-galactoglucan, Agrobacterium fermentation broth containing L-β-galactoglucan, and crude L-β-galactoglucan polysaccharide in preparing a product for improving the health status of animals. Furthermore, in the step of improving the health status of domesticated animals, the domesticated animals are selected from mammals. Furthermore, the mammal is selected from livestock and pets; for example, the livestock include pigs, cattle, and sheep; and the pets include dogs and cats. Among them, the improvement of the health status of livestock refers to one or more of promoting growth, promoting immunity, improving intestinal microbial flora, and reducing diarrhea. In a specific embodiment of the present invention, the use of L-β-galactoglucan, Agrobacterium fermentation broth containing L-β-galactoglucan or crude L-β-galactoglucan polysaccharide can effectively reduce the diarrhea rate of weaned piglets and promote the growth of piglets. In a specific embodiment of the present invention, in the improvement of the health of livestock, the amount of L-β-galactoglucan used is 400-600 g / ton of ordinary feed. The above amount is the amount of crude polysaccharide (total sugar purity is about 60% or more) in the feed. If the purity is converted to the amount of purified polysaccharide (total sugar purity is 90% or more), it is about 240-470 g / ton. Among them, the improvement of the health status of the pet refers to one or more of reducing obesity, improving palatability, increasing the relative abundance of intestinal probiotics, improving stool shape, and improving coat quality. In a specific embodiment of the present invention, the pet is a dog. In a specific embodiment of the present invention, in the improvement of the health of pets, the percentage of L-β-galactoglucan added to the diet is 0.25-0.5%. The above amount is the amount of crude polysaccharide (total sugar purity is about 60% or more) in the diet, and if the purity is converted to the amount of purified polysaccharide (total sugar purity is 90% or more), it is about 0.15-0.40%. Palatability refers to the attractiveness and acceptability of feed or food to animals. Animals will decide whether they like to eat a certain food based on the taste, flavor, smell, texture and other characteristics of the food. This characteristic is called palatability. Improving the palatability of feed has a good significance for improving the health of animals, which is mainly reflected in the following aspects: (1) Promote appetite and feed intake: When feed has good palatability, it can stimulate the appetite of animals and make them more willing to eat. This helps animals take in more nutrients to meet their growth and development needs. (2) Improve nutrient absorption rate: When animals eat, if the feed tastes good and is easy to digest, the absorption rate of nutrients will also increase accordingly. This means that animals can use the nutrients in the feed more effectively, reduce waste, and also help improve the growth rate and health of animals. (3) Reduce digestive tract diseases: Good palatability can reduce the irritation of feed to the animal’s digestive tract and reduce the occurrence of digestive tract diseases. For example, if the feed is too rough or difficult to digest, it may cause gastrointestinal diseases in animals, affecting their health and production performance. (4) Improve animal welfare: Improving the palatability of feed can also help improve animal welfare. When animals can eat food that tastes good and is nutritious, their quality of life and sense of well-being will also improve accordingly. This helps reduce the stress response of animals and improve their production performance and health. (5) Promote healthy growth of animals: By improving the palatability of feed, animals can take in more nutrients and use them more efficiently. This helps promote the healthy growth of animals and improves their weight, meat production, milk production and other production performance indicators. Improved coat quality means your pet's skin and hair are in healthier condition, which is usually reflected in the shine, softness, density of the hair, and the health of the skin. The need for weight loss and weight gain in feeding pets (such as dogs and cats) and livestock (such as pigs, cattle and sheep) mainly stems from their different physiological characteristics, breeding purposes and health considerations. Among them, feeding pets (such as dogs and cats) often requires weight loss: (1) Health factors: Overweight pets may lead to a series of health problems, such as heart disease, joint disease, diabetes, etc. Therefore, keeping the pet's weight within a healthy range is one of the important goals of pet feeding. (2) Living habits: Pets usually need more time for activities and play. Excessive weight may affect their ability to move and reduce their quality of life. (3) Breed characteristics: Some pet breeds are naturally prone to being overweight, so for these breeds, owners need to pay more attention to controlling their diet to prevent them from being overweight. Livestock (such as pigs, cattle, and sheep) are often fed to increase their weight: (1) Economic value: The weight gain of livestock is usually directly related to their economic value. For example, the weight gain of pigs, cattle, and sheep can improve their meat quality and yield, thereby increasing farmers' economic income. (2) Purpose of breeding: The main purpose of breeding livestock is to provide meat, dairy products or other agricultural products. Therefore, weight gain is key to meeting these needs. (3) Growth characteristics: Livestock require a lot of nutritional support during their growth to meet their growth and development needs. Providing adequate feed and nutrition can promote livestock weight gain and improve production efficiency. Common skin care products include but are not limited to hydrating spray, moisturizing spray, toner, essence, essence, lotion, face cream, facial cleanser, facial mask, sunscreen, etc. In the skin care products, in addition to the L-β-galactoglucan, the Agrobacterium fermentation broth containing L-β-galactoglucan, and the crude L-β-galactoglucan polysaccharide of the present invention, commonly used components may also be used, for example: Moisturizer: In order to provide the skin with the moisture it needs, it often contains moisturizers such as hyaluronic acid, glycerin, butylene glycol, trehalose, etc. These ingredients can lock in moisture in the skin and keep the skin hydrated. Whitening ingredients: Common ingredients include niacinamide (vitamin B3), arbutin, vitamin C (ascorbic acid), etc. These ingredients can inhibit the formation of melanin and brighten the skin. Anti-aging ingredients: often contain collagen, peptides (such as palmitoyl pentapeptide-4), vitamin E, retinol, etc. These ingredients can stimulate skin cell regeneration, improve skin elasticity, and reduce fine lines and wrinkles. Soothing ingredients: May contain allantoin, aloe extract, chamomile extract, etc. These ingredients can relieve skin irritation, redness, swelling and discomfort. Antioxidants: In order to resist free radical damage to the skin, it often contains antioxidants, such as green tea extract, grape seed extract, vitamin C, etc. These ingredients can protect the skin from environmental pollution and ultraviolet damage. Cleansers: Common ingredients include carbon black, kaolin, bentonite, etc. These ingredients can absorb oil and dirt on the surface of the skin and deeply clean the pores. Preservatives: Preservatives need to be added to extend the shelf life of the product. Common preservatives include phenoxyethanol, methylparaben, etc. However, it should be noted that excessive use of preservatives may cause irritation to the skin. Astringents: such as aluminum chloride, citric acid, etc., help shrink pores. Emulsifier: helps the water phase and oil phase mix to form a stable emulsion. Stabilizer: Prevents the product from separating or deteriorating. Aqueous phase: Mainly water, may also contain some water-soluble humectants. Oil phase: such as jojoba oil, squalane, etc., which provide oil and protection for the skin. Surfactant: It mainly plays the role of washing and foaming. Common ones include soap base, alkyl sulfate ester salt, N-acyl methyl taurine, etc. Other additives: such as flavors, pigments, etc., used to improve the appearance and smell of the product. In the present invention, the form of the product includes but is not limited to medicines, health products, foods, cosmetics, skin care products, veterinary drugs, feed, feed additives, etc. The product of the invention comprises at least one of L-β-galactoglucan, Agrobacterium fermentation broth containing L-β-galactoglucan, and crude L-β-galactoglucan polysaccharide. Appropriate auxiliary materials can be added to the product of the present invention as required. The excipients described in the present invention are a general term for all additional materials other than the main component. The excipients should have the following properties: (1) no toxic effects on the body and almost no side effects; (2) stable chemical properties and not easily affected by temperature, pH, storage time, etc.; (3) no incompatibility with the main drug and no impact on the efficacy and quality inspection of the main drug; (4) no interaction with the packaging material. The excipients in the present invention include but are not limited to fillers (diluents), lubricants (glidants or anti-adhesive agents), dispersants, wetting agents, adhesives, regulators, solubilizers, antioxidants, antibacterial agents, emulsifiers, disintegrants, etc. Binders include syrup, gum arabic, gelatin, sorbitol, tragacanth, cellulose and its derivatives (such as microcrystalline cellulose, sodium carboxymethyl cellulose, ethyl cellulose or hydroxypropyl methyl cellulose, etc.), gelatin slurry, syrup, starch slurry or polyvinyl pyrrolidone, etc.; fillers include lactose, powdered sugar, dextrin, starch and its derivatives, cellulose and its derivatives, inorganic calcium salts (such as calcium sulfate, calcium phosphate, calcium hydrogen phosphate, precipitated calcium carbonate, etc.), sorbitol or glycine, etc.; lubricants include micropowder silica gel, magnesium stearate, talc, aluminum hydroxide, boric acid, hydrogenated vegetable oil, polyethylene glycol, etc.; disintegrants include starch and its derivatives (such as sodium carboxymethyl starch, sodium starch glycolate , pregelatinized starch, modified starch, hydroxypropyl starch, corn starch, etc.), polyvinyl pyrrolidone or microcrystalline cellulose, etc.; wetting agents include sodium dodecyl sulfate, water or alcohol, etc.; antioxidants include sodium sulfite, sodium bisulfite, sodium metabisulfite, dibutyl benzoic acid, etc.; antibacterial agents include 0.5% phenol, 0.3% cresol, 0.5% trichlorobutanol, etc.; regulators include hydrochloric acid, citric acid, potassium hydroxide (sodium), sodium citrate and buffers (including sodium dihydrogen phosphate and disodium hydrogen phosphate), etc.; emulsifiers include polysorbate-80, sorbitan oleate, poloxamer F-68, lecithin, soybean lecithin, etc.; solubilizers include Tween-80, bile, glycerol, etc. There is no particular limitation on the administration of the L-β-galactoglucan, the Agrobacterium fermentation broth containing L-β-galactoglucan, and the crude L-β-galactoglucan polysaccharide of the present invention. Representative administration methods include (but are not limited to): oral, parenteral (intravenous, intramuscular or subcutaneous), and topical administration. Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Solid dosage forms such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances, etc. Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures of these substances, and the like. Dosage forms for topical administration of the compounds of the invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required. The main types of skin repair products are as follows: 1. Cream refers to a uniform semisolid preparation formed by dissolving or dispersing the raw material drug in an emulsion-type matrix. Excipients for creams usually include emulsifiers, stabilizers, moisturizers, preservatives, etc. 2. Gel is a semisolid dosage form, which is characterized by fluidity and thixotropy under certain conditions. The excipients of gels include gel matrix, moisturizers, preservatives, etc. For example, recombinant human epidermal growth factor gel is a gel used to promote skin wound healing. 3. Solution: A solution refers to a clear liquid preparation made by dissolving the raw material drug in a suitable solvent. The auxiliary materials of solution mainly include solvents, preservatives, stabilizers, etc. Solution is suitable for cleaning, antipruritic, disinfection, astringency, etc. 4. Ointment is a semisolid preparation for external use in which the drug is dissolved or dispersed in a suitable matrix. The main excipients of ointments are base, preservatives, moisturizers, etc. Ointments are often used for chronic inflammatory skin lesions, such as eczema, dermatitis, etc. 5. Dressing is a material that covers the surface of skin wounds and is used to protect the wound, absorb exudate, promote healing, etc. There are many types of dressings, including gauze, vaseline gauze, synthetic fiber cloth, hydrocolloid dressing, hydrogel dressing, etc. Different dressings are suitable for different types of wounds and healing stages. 6. External spray is a liquid preparation for external use on the skin, mucous membranes, etc., which is sprayed out in mist form by a special device to spray drug solutions, emulsions or suspensions. The excipients of topical sprays include solvents, propellants, stabilizers, etc. This dosage form is suitable for some drugs that need to be evenly distributed on the wound surface. Among veterinary products, common dosage forms include but are not limited to: (1) Liquid dosage form: refers to the form of drugs, feed or feed additives in liquid state, such as solutions, suspensions, etc. This dosage form is suitable for rapid administration or addition to drinking water for easy self-intake by animals. (2) Semisolid dosage form: refers to the form of drugs, feed or feed additives in a semisolid state, such as ointments, pastes, etc. This dosage form is suitable for topical administration or application on the skin of animals. (3) Solid dosage form: refers to the form of drugs, feed or feed additives in a solid state, such as tablets, granules, pills, etc. This dosage form is suitable for direct feeding or adding to feed, and has the advantages of convenient storage and transportation. (4) Microcapsule dosage form: refers to the form in which drugs, feed or feed additives are encapsulated in tiny capsules. This dosage form can control the release rate and location of the drug and improve the stability and bioavailability of the drug. Veterinary solution is a drug made by dissolving non-volatile active ingredients in a specific solvent (such as water, alcohol, oil, etc.) for oral or external use. The solution of this dosage form is generally clear, but the oil-soluble solution may not be clear. Common excipients include: 1. Solvent: Water: The most common solvent used to prepare aqueous solutions. Ethanol: Used to prepare alcoholic solutions and sometimes to increase the solubility of drugs. Glycerol: As an oily solvent, it can be used to prepare oil solutions. 2. Stabilizer: Antioxidants: such as vitamin E, sodium sulfite, etc., used to prevent drugs from oxidative deterioration. Preservatives: such as sodium benzoate, potassium sorbate, etc., are used to extend the shelf life of the solution. 3. Buffer: Used to adjust the pH of the solution to maintain the stability of the drug, for example, phosphate buffer, acetate buffer, etc. 4. Surfactant: Used to improve the solubility and dispersibility of drugs, such as polysorbate 80, sodium lauryl sulfate, etc. 5. Solvent: Used to help poorly soluble drugs dissolve in water, such as urea, polyethylene glycol, etc. 6. Solubilizer: Used to increase the solubility of drugs in solutions, such as Tween series, poloxamer, etc. 7. Flavor correctors: Used to improve the taste of the solution, such as stevia, citric acid, etc. 8. Colorant: Used to add color to solutions for easy identification and differentiation, such as food coloring. Veterinary suspension refers to the suspension of drugs in water or oil matrix to form a stable suspension, which is convenient for animals to use. The role of suspension in the use of veterinary drugs: (1) Extending the shelf life: Suspensions can effectively maintain the stability of drugs, allowing them to maintain high quality over a longer period of time. (2) Improving drug quality: Suspensions have a good protective effect on the drug's cytoplasm, pH, and nutritional elements, which can reduce drug quality problems that may occur during later use and effectively improve the therapeutic effect. (3) Ease of use: Suspensions improve the consistency of the drug, thereby reducing unnecessary difficulties. During animal medication, this suspension can increase the viability and vitality of the drug, further improving the therapeutic effect. In addition to solvent excipients, common suspension excipients also include excipients that help solid drug particles to be evenly suspended in the solution, such as: (1) Physical suspending agents: They mainly form a thick dispersed phase through polymer action to inhibit or prevent solid particles from agglomerating. Common physical suspending agents include sodium carboxymethyl cellulose (CMC), sodium glutamate, gelatin, etc. Since 10 examples are required, but there are not enough common excipients to list 10, only some examples are listed below. (2) Physical and chemical suspending agents: Through physical and chemical reactions or actions, a uniform shell layer is formed. Common physical and chemical suspending agents include magnesium aluminum silicate, functional silicates, liquid paraffin, etc. (3) Surfactants: They create a dispersed phase by adsorbing on the solid surface, preventing the movement of particles and forming a highly dispersed system. Surfactants are mainly divided into anionic, cationic, nonionic and zwitterionic surfactants. Specific examples may include various anionic surfactants (such as sodium dodecyl sulfate), cationic surfactants (such as hexadecyltrimethylammonium bromide), nonionic surfactants (such as polyoxyethylene alkylphenol ethers) and zwitterionic surfactants (such as dodecyl betaine). (4) Biological suspending agents: mainly affect the charge characteristics and stability of particles through the characteristics of biological reactions, thereby achieving the purpose of dispersion. Common biological suspending agents include bovine serum albumin, chicken ovalbumin, etc. In addition, some excipients with special functions are also included, such as thickeners, chelating agents, pH adjusters, etc. The specific selection depends on the properties of the drug and application requirements. Veterinary ointment refers to a semi-solid topical preparation with appropriate consistency made by evenly mixing the drug with a suitable matrix. This type of preparation is mostly a paste dosage form with a high consistency made by mixing the drug with excipients such as vaseline and oils, and is mainly for external use. The excipients of ointments mainly include: 1. Matrix: Vaseline: A commonly used oily base with good moisturizing and lubricating properties. Lanolin: A natural animal fat with good moisturizing properties and stability. Stearic acid: a commonly used oily base, used in combination with stearyl glyceride, etc. Paraffin: A mixture of solid hydrocarbons that increases the consistency and stability of ointments. Vegetable oils: such as soybean oil, peanut oil, etc., can be used as oily bases for ointments. 2. Thickener: Magnesium aluminum silicate: has adsorption and thickening effects and is often used to adjust the consistency of ointments. Sodium carboxymethylcellulose (CMC): A water-soluble cellulose derivative that can be used as a thickener for oil-in-water ointments. Polyvinyl alcohol (PVA): A high molecular weight polymer that can be used to adjust the viscosity and consistency of ointments. 3. Preservatives: Benzoic acid: a commonly used acidic preservative that has inhibitory effects on a variety of microorganisms. Ethylparaben: A broad-spectrum antimicrobial agent that is effective against both fungi and bacteria. Propylene glycol: It has preservative and moisturizing properties and is often used in ointments. 4. Moisturizer: Glycerin: It is highly hygroscopic and can form hydrogen bonds with water to keep the skin hydrated. Glycerin: Similar to glycerin, it has good moisturizing effect. 5. Antioxidants: Vitamin E: Antioxidant that prevents drugs from oxidative deterioration. Butylated hydroxyanisole (BHA): A commonly used antioxidant used to prevent oxidation of oily matrices. Veterinary paste is a semi-solid paste preparation with high hardness, large water absorption capacity, and low greasiness. There are certain differences between paste and ointment: 1. Texture and appearance: Ointment: A semisolid, milky white, gel-like substance that is usually smooth and easy to apply. Paste: A viscous liquid or semisolid substance with a relatively high hardness, which is usually harder and drier than an ointment and is less greasy and less occlusive than an ointment. 2. Application: Ointments: Mainly used to treat minor burns, abrasions and other small skin injuries to relieve pain and promote healing. Paste: Suitable for chronic skin diseases such as subacute dermatitis or eczema. It has moisture absorption, drying and antipruritic effects. It is often used to treat large areas of trauma or infected wounds, such as incisions after surgery. 3. Usage: Ointment: Usually used by external application, it can be applied directly to the affected area and gently massage until absorbed. Paste: Apply an appropriate amount of paste directly on the wound, and then bandage it with sterile gauze. 4. Main differences in auxiliary materials: (1) Matrix: Ointments: Common bases include vaseline, lanolin, vegetable oil, etc. These bases can form relatively soft and delicate ointments. Paste: The base is mostly a hydrocarbon base or a water-in-oil emulsion base. The paste formed after mixing with the powder is usually harder and drier. (2) Thickener: Ointments: Thickeners are rarely used because ointments already have a good consistency. Paste: Since the paste needs to have a higher hardness and greater water absorption capacity, more thickeners may be used, such as magnesium aluminum silicate, sodium carboxymethyl cellulose, etc. Solid dosage forms include capsules, tablets, pills, powders and granules etc. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. Veterinary microcapsules refer to microcapsules that use natural or synthetic polymer materials (capsule materials) to encapsulate solid or liquid drugs (capsule cores). This dosage form uses a specific preparation process to embed the drug in a specific polymer carrier at high temperature, and then forms uniform drug-loaded microspheres through instant spray condensation. These microspheres are subjected to specific pH, intestinal lipase and other conditions in the animal body, and can achieve sustained release, controlled release or intestinal release of the drug. The excipients of veterinary microcapsules mainly include the following: 1. Polymer carrier: For example: polylactic acid (PLA), polylactic acid-glycolic acid copolymer (PLGA), gelatin, chitosan, etc. These polymer materials have good biocompatibility and degradability and can be used as the main carrier materials of microcapsules. 2. Emulsifier: For example: polysorbate 80 (Tween 80), sodium dodecyl sulfate (SDS), etc. Emulsifiers play a role in reducing interfacial tension, promoting drug dispersion and stabilizing the microcapsule structure during the preparation of microcapsules. 3. Thickener: For example: methyl cellulose, hydroxyethyl cellulose, polyvinyl alcohol (PVA), etc. Thickeners can increase the consistency and stability of microcapsules and prevent drug precipitation and stratification during preparation and storage. 4. Stabilizer: For example: mannitol, sorbitol, disodium hydrogen phosphate, etc. Stabilizers can prevent physical and chemical changes in microcapsules during storage and use, ensuring the stability and effectiveness of the drug. 5. Antioxidants: For example: vitamin E, butylated hydroxyanisole (BHA), propyl gallate, etc. Antioxidants can prevent the drugs in the microcapsules from becoming ineffective due to oxidation and extend the shelf life of the microcapsules. The beneficial effects of the present invention are as follows: (1) The present invention provides a novel structure of L-β-galactoglucan; (2) The polysaccharide fermentation process of the present invention is simple, low-cost, and suitable for industrial production; (3) The wastewater generated during the fermentation process does not contain toxic substances and can be reused; (4) The polysaccharide of the present invention not only has the effect of treating and / or preventing diseases related to glucose metabolism disorders and liver damage, but also has the effects of anti-aging, skin repair, and improving the health status of animals. BRIEF DESCRIPTION OF THE DRAWINGS FIG1 is a graph showing the TLC results of L-β-galactoglucan samples and monosaccharide standards after acid hydrolysis; Fig. 2 is a HPLC detection spectrum of L-β-galactoglucan after acid hydrolysis and monosaccharide standard; Fig. 3 is the FI-IR spectrum of L-β-galactoglucan; FIG4 is a GC spectrum of acetylation of L-β-galactoglucan; FIG5 is a total ion current spectrum of the sugar alcohol acetate derivatives after methylation of L-β-galactoglucan; Figure 6 shows L-β-galactoglucan 1 H-NMR spectrum (500 MHz, 298 K); Figure 7 shows L-β-galactoglucan 13 C-NMR spectrum (500 MHz, 298 K); FIG8 is a DEPT135 spectrum (500 MHz, 298 K) of L-β-galactoglucan; FIG9 is a COSY spectrum of L-β-galactoglucan (500 MHz, 298 K); FIG10 is a HSQC spectrum of L-β-galactoglucan (500 MHz, 298 K); FIG11 is the HMBC spectrum of L-β-galactoglucan (500 MHz, 298 K); FIG12 shows the glucose level of zebrafish after L-β-galactoglucan treatment in effect experiment 1; FIG13 is a graph showing the fluorescence intensity of zebrafish pancreatic β cells after treatment with L-β-galactoglucan in effect test 2; FIG14 is a typical graph of the fluorescence intensity of zebrafish pancreatic β cells after treatment with L-β-galactoglucan in effect experiment 2; FIG15 is a histogram of the fluorescence intensity of zebrafish pancreatic β cells after treatment with L-β-galactoglucan in effect test 2; FIG16 is a line graph showing blood glucose levels in mice after treatment with L-β-galactoglucan in effect test 3; FIG17 is a schematic diagram of the analysis of zebrafish tail fin length after L-β-galactoglucan treatment in effect experiment 4; FIG18 is a typical graph of the tail fin length of zebrafish after L-β-galactoglucan treatment in effect experiment 4; FIG19 is a bar graph of zebrafish tail fin length after L-β-galactoglucan treatment in effect test 4; FIG20 is a typical image of angiogenesis in zebrafish wounds after L-β-galactoglucan treatment in effect experiment 5; FIG21 shows the incidence of neovascularization in zebrafish after treatment with L-β-galactoglucan in effect test 5; FIG22 is a schematic diagram of the analysis site for the clearance of apoptotic cells in zebrafish injury sites after treatment with L-β-galactoglucan in effect experiment 6; FIG23 is a typical image of apoptotic cells in the injured part of zebrafish after treatment with L-β-galactoglucan in effect experiment 6; FIG24 is a histogram of the fluorescence intensity of apoptotic cells in zebrafish tissue injury sites after L-β-galactoglucan treatment in effect experiment 6; FIG25 is a typical graph of fluorescence intensity of zebrafish macrophages after L-β-galactoglucan treatment in effect experiment 7; FIG26 is a histogram of fluorescence intensity of zebrafish macrophages after treatment with L-β-galactoglucan in effect test 7; FIG27 is a schematic diagram of the analysis of the number of residual fluorescent microspheres in zebrafish in effect experiment 8; FIG28 is a typical graph showing the number of fluorescent microspheres remaining in zebrafish after treatment with L-β-galactoglucan in effect test 8; FIG29 shows the number of fluorescent microspheres remaining in zebrafish after L-β-galactoglucan treatment in effect test 8; FIG30 is a schematic diagram of the analysis of fluorescence intensity of zebrafish T cells in effect experiment 9; FIG31 is a typical graph of the fluorescence intensity of zebrafish T cells after treatment with L-β-galactoglucan in effect experiment 9; FIG32 is a histogram of the fluorescence intensity of zebrafish T cells after treatment with L-β-galactoglucan in effect experiment 9; FIG33 is a typical graph showing the number of neutrophils in zebrafish tail blood vessels after L-β-galactoglucan treatment in effect experiment 10; FIG34 is a graph showing the number of neutrophils in the blood vessels of the tail of zebrafish after treatment with L-β-galactoglucan in effect test 10; FIG35 is a graph showing AST activity in zebrafish tissues after L-β-galactoglucan treatment in effect experiment 11; FIG36 is a graph showing the activity of ALT in zebrafish tissues after treatment with L-β-galactoglucan in effect experiment 12; FIG37 is a typical diagram of the liver tissue structure of zebrafish after L-β-galactoglucan treatment in effect experiment 13; FIG38 is a bar graph of ROS fluorescence values ​​of zebrafish after treatment with L-β-galactoglucan in effect test 14; FIG39 is a bar graph of ATP chemical light values ​​of zebrafish after treatment with L-β-galactoglucan in effect experiment 15; FIG40 is a bar graph showing the lactic acid content of zebrafish after treatment with L-β-galactoglucan in effect experiment 16; FIG41 is a schematic diagram of fluorescence intensity analysis of zebrafish intestinal flora after L-β-galactoglucan treatment in effect experiment 17; FIG42 is a typical graph of fluorescence intensity of zebrafish intestinal flora after treatment with sugar L-β-galactoglucan in effect experiment 17; FIG43 is a histogram of the fluorescence intensity of Lactobacillus brevis in the zebrafish intestine after treatment with L-β-galactoglucan in effect experiment 17; FIG44 is a schematic diagram of the analysis of zebrafish tail area after L-β-galactoglucan treatment in effect experiment 18; Figure 45 is a typical diagram of the tail area of ​​zebrafish after L-β-galactoglucan treatment in effect experiment 18; Figure 46 shows the tail area of ​​zebrafish after L-β-galactoglucan treatment in effect experiment 18; FIG47 is a schematic diagram of the analysis of β-galactosidase staining intensity in zebrafish after L-β-galactoglucan treatment in effect experiment 19; FIG48 is a typical graph of the β-galactosidase staining intensity of zebrafish after treatment with L-β-galactoglucan in effect experiment 19; FIG49 shows the β-galactosidase staining intensity of zebrafish after L-β-galactoglucan treatment in effect experiment 19; Figure 50 is a graph showing telomerase activity in zebrafish after treatment with L-β-galactoglucan in effect experiment 20; Figure 51 is a graph showing the relative expression of col1a1a gene in effect experiment 21; Fig. 52 is a graph showing the relative expression of col1a1b gene in effect experiment 21; FIG53 is a schematic diagram of the analysis of melanin signal intensity at the damaged part of zebrafish tissue after L-β-galactoglucan treatment in effect experiment 22; FIG54 is a typical graph of melanin signal intensity at the damaged part of zebrafish tissue after L-β-galactoglucan treatment in effect experiment 22; FIG55 is a histogram of melanin signal intensity at the damaged part of zebrafish tissue after treatment with L-β-galactoglucan in effect experiment 22; Figure 56: Composition of bacterial abundance at the TOP10 phylum level in each group; Figure 57: Composition of bacterial abundance at the TOP30 genus level in each group; Figure 58 Histogram of LEfSe analysis and LDA scores of the effect of L-β-galactoglucan on the colonic microbial composition of weaned piglets, showing the biomarker clusters (LDA score > 2); Figure 59 Fecal microbial composition. A: Venn diagram of fecal microorganisms at the genus level; B: fecal microbial β diversity (PCOA analysis); C: phylum level community composition; D: genus level community composition; n = 8; Figure 60 Effect of biopolysaccharides on the relative expression level of IL-6 gene in HaCaT cells induced by Malassezia. DETAILED DESCRIPTION In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with embodiment and effect test.It should be understood that the specific embodiments and effect test described herein are only used to explain the present invention and are not intended to limit the present invention.In addition, if not clearly stated, all reagents adopted in the following embodiments are all commercially available, or can be synthesized according to this article or known methods, and for the reaction conditions not listed, they are also easily obtained by those skilled in the art. [Corrected on 24.10.2024 according to Rule 91] The Agrobacterium sp. FN01 described in the present invention was isolated from the soil of the western Sichuan Plateau and deposited in the China Center for Type Culture Collection (CCTCC) on March 2, 2023, with the deposit number: CCTCC No. M2023226, address: Wuhan University, Wuhan, China. Example 1 Preparation of L-β-galactoglucan (1) Preparation of Agrobacterium FN01 seed solution The culture medium formula is 1.0% peptone, 0.5% yeast powder, and 1.0% sodium chloride dissolved in drinking tap water, and the pH is adjusted to 6.5-7.5 with sodium hydroxide solution. After sterilization at 121°C for 30 minutes, Agrobacterium FN01 is inoculated after cooling, and the Agrobacterium FN01 seed liquid is obtained after aeration and stirring and culture for 20 hours. (2) Preparation of culture medium 3.0% white sugar, 0.2% sodium nitrate, 0.1% peptone, 0.2% potassium dihydrogen phosphate, 0.02% magnesium sulfate, 0.002% ferrous sulfate, 0.0012% manganese sulfate, 0.01% calcium chloride, 0.05% defoamer were dissolved in drinking tap water, and the pH was adjusted to 6.7 with sodium hydroxide solution. Sterilized at 121°C for 30 minutes, and cooled to obtain the culture solution. (3) Preparation of fermentation broth The seed liquid is inoculated into the culture liquid, and the inoculation amount is 5% of the culture liquid. The fermentation conditions are as follows: 1) The temperature is controlled at 28-32°C; 2) The pH is controlled between 6.5 and 7.5 using dilute hydrochloric acid or sodium hydroxide solution; 3) The ventilation volume: 0.2-0.4 vvm for 0-24 hours; 0.5-0.7 vvm for 24-48 hours; 0.9-1.0 vvm for 48 hours until the end of fermentation; 4) The stirring speed: 60 rpm for 0-24 hours; 100 rpm for 24-48 hours; 150 rpm for 48 hours until the end of fermentation. The fermentation is completed after 65 hours of cultivation, and the fermentation liquid containing L-β-galactoglucan is prepared. (4) Preparation of crude L-β-galactoglucan Add 2.5 times the volume of 95% ethanol to the fermentation liquid to precipitate the fermentation liquid, and take the precipitate and dry it to obtain crude L-β-galactoglucan. (5) Purification of L-β-galactoglucan The crude L-β-galactoglucan was dissolved in water to form a 1.5% solution, and 0.1% sodium hydroxide was added to mix. After heating to 85°C, 1.5% diatomaceous earth was added to mix. Impurities were removed by plate and frame filtration and the filtrate was collected. 3.5 times the volume of 95% ethanol was added to precipitate the polysaccharide; the precipitate was pressed dry, dried at 60°C, and crushed to obtain a pure L-β-galactoglucan solid powder. The total sugar content was measured to be 91.7% with reference to the national standard GB / T 15672-2009 "Determination of total sugar content in edible fungi". Example 2 Preparation of L-β-galactoglucan (1) Preparation of Agrobacterium FN01 seed solution The culture medium formula is 1.0% peptone, 0.5% yeast powder, and 1.0% sodium chloride dissolved in drinking tap water, and the pH is adjusted to 6.5-7.5 with sodium hydroxide solution. After sterilization at 121°C for 30 minutes, Agrobacterium FN01 is inoculated after cooling, and the Agrobacterium FN01 seed liquid is obtained after aeration and stirring and culture for 20 hours. (2) Preparation of culture medium 5.0% maltose, 0.3% potassium nitrate, 0.1% peptone, 0.1% potassium dihydrogen phosphate, 0.04% magnesium sulfate, 0.001% ferrous sulfate, 0.0006% manganese sulfate, 0.005% calcium chloride, 0.2% defoamer were dissolved in drinking tap water, and the pH was adjusted to 6.7 with sodium hydroxide solution. Sterilized at 121°C for 30 minutes, and cooled to obtain the culture solution. (3) Preparation of fermentation broth The seed liquid is inoculated into the culture liquid, and the inoculation amount is 1% of the culture liquid. The fermentation conditions are as follows: 1) the temperature is controlled at 28-32°C; 2) the pH is controlled between 6.5 and 7.5 with dilute hydrochloric acid or sodium hydroxide solution; 3) the ventilation volume: 0-24h, 0.2-0.4vvm; 24-48h, 0.5-0.7vvm; 48h to the end of fermentation, 0.9-1.0vvm; 4) the stirring speed: 0-24h, 60rpm; 24-48h, 100rpm; 48h to the end of fermentation, 150rpm. The fermentation is completed after 80h of cultivation, and the fermentation liquid containing L-β-galactoglucan is prepared. (4) Preparation of crude L-β-galactoglucan Add 3 times the volume of 95% ethanol to the fermentation liquid to precipitate the fermentation liquid, take the precipitate and dry it to obtain crude L-β-galactoglucan. (5) Purification of L-β-galactoglucan The crude L-β-galactoglucan was dissolved in water to form a 1.5% solution, and 0.1% sodium hydroxide was added to mix. After heating to 85°C, 1.5% diatomaceous earth was added to mix. Impurities were removed by plate and frame filtration and the filtrate was collected. 4 times the volume of 95% ethanol was added to precipitate the polysaccharide; the precipitate was pressed dry, dried at 60°C, and crushed to obtain a pure L-β-galactoglucan solid powder. The total sugar content was measured to be 90.5% with reference to the national standard GB / T 15672-2009 "Determination of total sugar content in edible fungi". Example 3 Preparation of L-β-galactoglucan (1) Preparation of Agrobacterium FN01 seed solution The culture medium formula is 1.0% peptone, 0.5% yeast powder, and 1.0% sodium chloride dissolved in drinking tap water, and the pH is adjusted to 6.5-7.5 with sodium hydroxide solution. After sterilization at 121°C for 30 minutes, Agrobacterium FN01 is inoculated after cooling, and the Agrobacterium FN01 seed liquid is obtained after aeration and stirring and culture for 20 hours. (2) Preparation of culture medium 5.0% maltose, 0.3% potassium nitrate, 0.1% peptone, 0.1% potassium dihydrogen phosphate, 0.04% magnesium sulfate, 0.001% ferrous sulfate, 0.0006% manganese sulfate, 0.005% calcium chloride, 0.2% defoamer were dissolved in drinking tap water, and the pH was adjusted to 6.7 with sodium hydroxide solution. Sterilized at 121°C for 30 minutes, and cooled to obtain the culture solution. (3) Preparation of fermentation broth The seed liquid is inoculated into the culture liquid, and the inoculation amount is 1% of the culture liquid. The fermentation conditions are as follows: 1) the temperature is controlled at 28-32°C; 2) the pH is controlled between 6.5 and 7.5 with dilute hydrochloric acid or sodium hydroxide solution; 3) the ventilation volume: 0-24h, 0.2-0.4vvm; 24-48h, 0.5-0.7vvm; 48h to the end of fermentation, 0.9-1.0vvm; 4) the stirring speed: 0-24h, 60rpm; 24-48h, 100rpm; 48h to the end of fermentation, 150rpm. The fermentation is completed after 80h of cultivation, and the fermentation liquid containing L-β-galactoglucan is prepared. (4) Enzymatic hydrolysis of fermentation broth The pH of the fermentation liquid was adjusted to 4.5-5.5 with hydrochloric acid, heated to 45-55°C, and 0.1% glucanase was added. Stirring was continued during the enzymolysis process. (5) Purification of L-β-galactoglucan The fermentation liquid after enzymatic hydrolysis is heated to 85-90°C, 1.5% diatomaceous earth is added and mixed, impurities are removed by plate and frame filtration and the filtrate is collected, the filtrate is concentrated by ultrafiltration to obtain L-β-galactoglucan concentrate, and the concentrate is spray-dried to obtain pure L-β-galactoglucan. Example 4 Structural analysis of polysaccharides (1) Polysaccharide molecular weight detection After testing, the molecular weight distribution of the polysaccharide of the present invention is 1x10 6 Da or more, and the weight average molecular weight is about 4982327 Da. (2) Monosaccharide composition and content results After the polysaccharide was acid-hydrolyzed, neutralized and concentrated, it was determined by TLC and HPLC. The results are shown in Figures 1 and 2, indicating that the polysaccharide acid-hydrolyzed solution only contained glucose and galactose, with percentages of approximately 96% and 4%. (3) FI-IR measurement results The FI-IR spectrum of the polysaccharide is shown in Figure 3. As can be seen from the figure, 3436.8cm -1 The strong broad peak at 2887.3cm is the stretching vibration absorption peak of OH. -1 It is the CH stretching vibration absorption peak of -CH2-, which is the characteristic peak of sugars. 1616.0cm -1 The stretching vibration absorption peak of carbonyl C=O is at 1000cm-1 ~1200cm -1 The broad extension of C–O–C and C–O in the range indicated the presence of carbohydrates. The 1043.5 cm -1 、1073.0cm -1 The absorption peaks at 893.0cm and 1161.0cm are related to CO stretching vibration. -1 The absorption peak at should be attributed to the bending vibration of the β-configuration terminal CH, which can be confirmed by further combining the NMR measurement results. From the infrared analysis results, it can be seen that the extracellular polysaccharide has the characteristic absorption peak of polysaccharide and contains β-type glycosidic bond connection. (4) Periodic acid oxidation The molar ratio of sodium periodate consumed and formic acid generated by the extracellular polysaccharide is 1:0.3819:0.1411. One mol of hexose equivalent polysaccharide sample consumes 0.3819 mol of periodate and produces 0.1411 mol of formic acid, indicating that the sample contains 14.11% of (1→) or (1→6) glycosidic bonds; the amount of sodium periodate consumed is more than twice the amount of formic acid generated, indicating that there are hexose residue glycosidic bonds in its structure that can be oxidized by periodate but do not produce formic acid, that is, it contains (1→2), (l→2,6), (l→4) or (l→4,6) glycosidic bonds, with a content of 9.97%. After periodic acid oxidation, the extracellular polysaccharide sample produced a large amount of glucose and galactose, indicating that there are hexose residue glycosidic bonds in the structure that are not oxidized by periodic acid, and may contain (1→3), (1→3,6), (1→2,3), (l→2,4), (l→3,4) or (l→2,3,4) glycosidic bonds. (5) Smith degradation The results of GC analysis of polysaccharide after periodic acid oxidation and Smith degradation are shown in Figure 4. By comparing the retention time, it can be seen that after the polysaccharide sample was subjected to periodic acid oxidation and Smith degradation and GC analysis, a small amount of glycerol was present, that is, a small amount of (1→2) or (1→6) glycosidic bonds were present in the extracellular polysaccharide; erythritol was basically undetectable in the product, so the sample almost did not contain (1→4) or (1→4,6) glycosidic bonds. Combined with the analysis of the periodic acid oxidation results, it can be seen that the extracellular polysaccharide contains 14.11% (1→) or (1→6) glycosidic bonds, 9.97% (1→2) or (l→2,6) glycosidic bonds, and may also contain (1→3), (1→3,6), (1→2,3), (l→2,4), (l→3,4) or (l→2,3,4) glycosidic bonds. (6) GC-MS analysis of methylation and acetylation products The total ion current spectrum of the sugar alcohol acetate derivatives after polysaccharide methylation is shown in Figure 5. The EI-MS spectra of the main products were compared with the database and attributed, and it was speculated that the glycosidic bond connection mode in the polysaccharide structure may be: ①Glcp(1→,②→3)Galp(1→,③→6)Galp(1→,④→4)Galp(1→,⑤→6)Glcp(1→,⑥→3,6)Galp(1→,⑦→4,6)Glcp(1→,⑧→2,3,6)Glcp(1→ and ⑨→2,3,4,6)Glcp(1→. (7) NMR results As shown in Figure 6, after D2O exchange, it can be observed that the hydrogen signals of the polysaccharide are mainly concentrated in the range of δ3.0-4.7 ppm, and δ4.3-4.7 ppm is the resonance region of the proton of the hexose anomeric proton of the polysaccharide, indicating that there is only β configuration in the polysaccharide, which is consistent with the results of infrared spectroscopy analysis. According to the polysaccharide samples 13 C-NMR and DEPT135-NMR spectra (Figures 7-8) show that its carbon signals are mainly concentrated in δ60-103.5ppm. Combined with the 2D-NMR spectra (COSY, HSQC and HMBC, Figures 9-11), in-depth analysis can be performed to attribute the main carbon and hydrogen signals. The carbon and hydrogen attributions of each residue may include: ①β-Galp (1→residue, ②→3)β-Galp (1→residue, ③→2,3)β-Glcp (1→residue, ④β-Glcp (1→ and ⑤→2)β-Glcp (1→residue. In summary, the exopolysaccharide is a high molecular weight, highly branched polysaccharide composed of β-glucose and β-galactose. It is speculated that the repeating unit structure of the exopolysaccharide is as follows, and the common name is suggested to be L-β-galactoglucan: Effect Test 1 Hypoglycemic Activity of L-β-galactoglucan 3dpf wild-type AB strain zebrafish were randomly selected and placed in beakers, with 30 zebrafish in each beaker. L-β-galactoglucan (concentrations shown in Table 1) was administered in water, and a normal control group and a model control group were set up at the same time, with a capacity of 25 mL per beaker. Except for the normal control group, all other experimental groups were injected with streptozotocin (STZ) in the yolk sac, and 0.15% egg yolk powder solution was administered in water during the day, and 3% glucose solution was administered in water at night to establish a zebrafish islet injury model. After 2 days of treatment at 28°C, the zebrafish were washed 3 times with standard dilution water, and data were collected with a blood glucose meter to analyze and statistically analyze the glucose level of the zebrafish. The statistical analysis results of this indicator were used to evaluate the protective efficacy of L-β-galactoglucan against islet injury. The statistical analysis results were expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 1 Blood glucose level (n=10) Compared with the model control group, ***p<0.001 As shown in Table 1 and FIG. 12 , L-β-galactoglucan has the effect of lowering blood sugar. Effect Test 2 Hypoglycemic Activity of L-β-galactoglucan 3dpf transgenic pancreatic β cell green fluorescence zebrafish were randomly selected and placed in beakers, with 30 zebrafish treated in each beaker. L-β-galactoglucan (concentrations shown in Table 2) was given in water, and a normal control group and a model control group were set up at the same time, with a capacity of 25mL per beaker. Except for the normal control group, all other experimental groups were injected with streptozotocin (STZ) in the yolk sac, and 0.15% egg yolk powder solution was given in water during the day, and 3% glucose solution was given in water at night to establish a zebrafish islet injury model. After 2 days of treatment at 28℃, 10 zebrafish were randomly selected from each group and placed under a fluorescence microscope to take pictures and save the pictures. NIS-Elements D 3.20 advanced image processing software was used for analysis and data collection. The fluorescence intensity of zebrafish islet β cells was analyzed and statistically analyzed, and the statistical analysis results of this indicator were used to evaluate the protective efficacy of L-β-galactoglucan against islet injury. The statistical analysis results are expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 2 Fluorescence intensity of pancreatic β cells (n=10) Compared with the model control group, *p<0.05, ***p<0.001 As shown in Table 2 and Figures 13 to 15, L-β-galactoglucan has the effect of protecting islet damage, which is specifically manifested in increasing the fluorescence intensity of pancreatic β cells. Effect Test 3 Hypoglycemic Activity of L-β-galactoglucan Thirty mice were randomly divided into three groups, with 10 mice in each group. After fasting for 24 hours, the mice were fed with 1g / kg starch, 1g / kg L-β-galactoglucan, and 1g / kg starch + 1g / kg L-β-galactoglucan, respectively. Blood samples were collected at 0h (before feeding), 0.5h, 1.0h, and 2.0h to measure the blood glucose of the mice. Table 3 Blood glucose level (mmol / L) The results are shown in Table 3 and Figure 16. L-β-galactoglucan can effectively control the rise of postprandial blood sugar. Effect test 4 Evaluation of the efficacy of L-β-galactoglucan in promoting tissue regeneration 3dpf wild-type AB strains were randomly selected in 6-well plates, and 30 zebrafish were treated in each well. L-β-galactoglucan was given in water (concentrations shown in Table 4), and human epidermal growth factor was used as a positive control at a concentration of 7.00μg / mL. A normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. Except for the normal control group, the rest of the experimental groups used surgical caudal fin amputation to establish a zebrafish tissue regeneration model. After 3 days of treatment at 28℃, 10 zebrafish were randomly selected from each experimental group and photographed under a dissecting microscope. NIS-Elements D 3.20 advanced image processing software was used to analyze and collect data, and the length of the zebrafish caudal fin was analyzed. The statistical analysis results of this indicator were used to evaluate the efficacy of L-β-galactoglucan in promoting tissue regeneration. The statistical analysis results were expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 4 Evaluation of the efficacy of L-β-galactoglucan in promoting tissue regeneration (n=10) Compared with the model control group, *p<0.05, ***p<0.001 As shown in Table 4 and Figures 17 to 19, L-β-galactoglucan has the effect of promoting tissue regeneration. Effect test 5 Evaluation of the efficacy of L-β-galactoglucan in promoting wound healing 2dpf transgenic vascular green fluorescent Flk1 strain zebrafish were randomly selected in 6-well plates, and 30 zebrafish were treated in each well. L-β-galactoglucan was given in water (concentrations are shown in Table 5), and human epidermal growth factor was used as a positive control at a concentration of 7.00 μg / mL. A normal control group and a model control group were set up at the same time, with a capacity of 3 mL per well. Except for the normal control group, all other experimental groups were injected with glacial acetic acid to establish a zebrafish tissue injury model. After 2 days of treatment at 28°C, the incidence of new blood vessels in the wound site of zebrafish in each experimental group was observed under a fluorescence microscope, and typical figures were collected. The statistical analysis results of the above indicators were used to evaluate the efficacy of L-β-galactoglucan in promoting wound healing. The statistical analysis results were expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 5 Evaluation of the efficacy of L-β-galactoglucan in promoting wound angiogenesis (n=30) Compared with the model control group, *p<0.05, ***p<0.001 As shown in Table 5 and Figures 20 to 21 , L-β-galactoglucan has the effect of promoting wound angiogenesis. Effect test 6 Evaluation of the efficacy of L-β-galactoglucan in promoting the clearance of apoptotic cells in the injured area 2dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well. L-β-galactoglucan (concentrations are shown in Table 6) was given in water, and human epidermal growth factor was used as a positive control at a concentration of 7.00 μg / mL. A normal control group and a model control group were set up at the same time, and the volume of each well was 3 mL. Except for the normal control group, all other experimental groups were injected with glacial acetic acid to establish a zebrafish tissue injury model. After treatment at 28℃ for 5 hours, the zebrafish in each experimental group were stained with a one-step TUNEL cell apoptosis detection kit. After staining, 10 zebrafish were randomly selected from each experimental group and placed under a fluorescence microscope for photography. NIS-Elements D 3.20 advanced image processing software was used to analyze and collect data, and the fluorescence intensity of apoptotic cells in the damaged part of zebrafish tissue was analyzed. The statistical analysis results of this indicator were used to evaluate the efficacy of L-β-galactoglucan in clearing apoptotic cells in the damaged part. The statistical analysis results are expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 6 Evaluation of the efficacy of L-β-galactoglucan in promoting the clearance of apoptotic cells at the injured site (n=10) Compared with the model control group, *p<0.05, **p<0.01, ***p<0.001 As shown in Table 6 and Figures 22 to 24, L-β-galactoglucan has the effect of promoting the removal of apoptotic cells in tissue damage sites. Effect test 7 Evaluation of the efficacy of L-β-galactoglucan in promoting the increase of macrophage number 3dpf transgenic macrophage green fluorescence strain zebrafish were randomly selected in 6-well plates, and 30 zebrafish were treated in each well. L-β-galactoglucan (concentrations are shown in Table 7) was given in water solution, and the positive control was Bailing capsule at a concentration of 15.0μg / mL. A normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. Except for the normal control group, all other experimental groups were intravenously injected with vinorelbine tartrate injection to establish a zebrafish macrophage reduction model. After 2 days of treatment at 28℃, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. The data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software, and the fluorescence intensity of zebrafish macrophages was analyzed. The statistical analysis results of this indicator were used to evaluate the efficacy of L-β-galactoglucan in increasing the number of macrophages. The statistical analysis results were expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 7 Evaluation of the efficacy of L-β-galactoglucan in increasing the number of macrophages (n=10) Compared with the model control group, *p<0.05, **p<0.01, ***p<0.001 As shown in Table 7 and Figures 25 and 26, L-β-galactoglucan has the effect of increasing the number of macrophages. Effect test 8 Evaluation of the efficacy of L-β-galactoglucan in promoting macrophage phagocytosis 3dpf wild-type AB strain zebrafish were randomly selected in 6-well plates, and 30 zebrafish were treated in each well. L-β-galactoglucan (concentrations shown in Table 8) was given in water solution, and the positive control was Bailing capsule at a concentration of 15.0μg / mL. A normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. Each experimental group was intravenously injected with vinorelbine tartrate injection and fluorescent microspheres to establish a macrophage phagocytic function inhibition model, and the normal control group was only injected with fluorescent microspheres. After 4 days of treatment at 28℃, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. Image~J image processing software was used to analyze and collect data, and the number of residual fluorescent microspheres in zebrafish was analyzed. The statistical analysis results of this indicator were used to evaluate the efficacy of L-β-galactoglucan in promoting macrophage phagocytosis. The statistical analysis results were expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 8 Evaluation of the efficacy of L-β-galactoglucan in promoting macrophage phagocytosis (n=10) Compared with the model control group, *p<0.05, **p<0.01, ***p<0.001 As shown in Table 8 and Figures 27 to 29, L-β-galactoglucan has the effect of promoting macrophage phagocytosis. Effect test 9 L-β-galactoglucan improves T cell reduction 3dpf transgenic T cell red fluorescence strain zebrafish were randomly selected in 6-well plates, and 30 zebrafish were treated in each well. L-β-galactoglucan (concentrations are shown in Table 9) was given in water solution, and the positive control Bailing capsule was 15.0μg / mL. A normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. Except for the normal control group, all other experimental groups were intravenously injected with vinorelbine tartrate injection to establish a zebrafish T cell reduction model. After 2 days of treatment at 28℃, 10 zebrafish were randomly selected from each experimental group and placed under a fluorescence microscope for photography. The data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software, and the fluorescence intensity of zebrafish T cells was analyzed. The statistical analysis results of this indicator were used to evaluate the efficacy of L-β-galactoglucan in improving T cell reduction. The statistical analysis results were expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 9 Evaluation of the efficacy of L-β-galactoglucan in improving T cell reduction (n=10) Compared with the model control group, **p<0.01, ***p<0.001 As shown in Table 9 and Figures 30 to 32, L-β-galactoglucan has the effect of improving T cell reduction. Effect trial 10 L-β-galactoglucan improves neutropenia 3dpf transgenic neutrophil green fluorescent zebrafish (MPX) were randomly selected in 6-well plates, and 30 zebrafish were treated in each well. L-β-galactoglucan (concentrations are shown in Table 10) was administered with water solution, and the positive control was 15.0μg / mL Bailing capsule. A normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. Except for the normal control group, all other experimental groups were intravenously injected with vinorelbine tartrate injection to establish a zebrafish neutropenia model. After 2 days of treatment at 28℃, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. The data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software. The number of neutrophils in the tail of zebrafish was analyzed, and the statistical analysis results of this indicator were used to evaluate the efficacy of L-β-galactoglucan in improving neutropenia. The statistical analysis results were expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 10 Evaluation of the efficacy of L-β-galactoglucan in improving neutropenia (n=10) Compared with the model control group, ***p<0.001 As shown in Table 10 and Figures 33 to 34 , L-β-galactoglucan has the effect of improving neutropenia. Effect test 11 Evaluation of the auxiliary protective effect (AST activity) of L-β-galactoglucan on alcoholic liver damage 3dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well. L-β-galactoglucan (concentrations are shown in Table 11), positive control metadoxine concentration of 298μg / mL, normal control group and model control group were set up at the same time, and the capacity of each well was 3mL. Except for the normal control group, all other experimental groups were given anhydrous ethanol to establish an alcoholic liver injury model. Three experiments were set up in parallel. After 2 days of treatment at 28℃, zebrafish samples were collected according to the instructions of the AST test kit, and AST levels were detected using a multifunctional microplate reader. The AST activity in zebrafish in each experimental group was analyzed, and the statistical analysis results of this indicator were used to evaluate the auxiliary protective effect of L-β-galactoglucan on alcoholic liver injury. The statistical analysis results are expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 11 Evaluation of the auxiliary protective effect (AST activity) of L-β-galactoglucan on alcoholic liver injury (n=3) Compared with the model control group, *p<0.05, **p<0.01, ***p<0.001 As shown in Table 11 and FIG. 35 , L-β-galactoglucan has the effect of reducing AST activity in tissues. Effect test 12 Evaluation of the auxiliary protective effect (ALT activity) of L-β-galactoglucan on alcoholic liver damage 3dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well. L-β-galactoglucan (concentrations are shown in Table 12) was given in water, and the positive control was metadoxine at a concentration of 298μg / mL. A normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. Except for the normal control group, all other experimental groups were given anhydrous ethanol in water to establish an alcoholic liver injury model. Three experiments were set up in parallel. After 2 days of treatment at 28℃, zebrafish samples were collected according to the instructions of the ALT test kit, and the ALT level was detected using a multifunctional microplate reader. The ALT activity in the zebrafish of each experimental group was analyzed, and the statistical analysis results of this indicator were used to evaluate the auxiliary protective effect of L-β-galactoglucan on alcoholic liver injury. The statistical analysis results are expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 12 Evaluation of the auxiliary protective effect (ALT activity) of L-β-galactoglucan on alcoholic liver injury (n=3) Compared with the model control group, *p<0.05, **p<0.01, ***p<0.001 As shown in Table 12 and FIG. 36 , L-β-galactoglucan has the effect of reducing the activity of ALT in tissues. Effect test 13: Effects on liver tissue structure 3dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well. L-β-galactoglucan (concentrations are shown in Table 12), positive control metadoxine concentration of 298μg / mL, normal control group and model control group were set up at the same time, and the capacity of each well was 3mL. Except for the normal control group, the other experimental groups were all treated with anhydrous ethanol to establish an alcoholic liver injury model. After 2 days of treatment at 28℃, the zebrafish in each experimental group were fixed with 4% tissue cell fixative, and after a series of dehydration-embedding-sectioning-staining-sealing steps, the zebrafish were subjected to histopathological HE staining analysis. The auxiliary protective effect of L-β-galactoglucan on alcoholic liver injury was evaluated by liver tissue pathology analysis. As shown in Figure 37, the pathological histological examination of the liver of zebrafish in the normal control group showed that the nuclei of the hepatocytes were regular and clear, without visible enlargement and vacuoles, and the hepatocyte structure was normal with clear edges; the pathological histological examination of the liver of zebrafish in the model control group showed that the hepatocyte structure was fuzzy and the liver tissue had fatty vacuolar degeneration (black arrow), indicating that the model was successfully established. The pathological histological examination of the liver of zebrafish in the positive control metadoxine showed that the hepatocyte structure was clearer than that in the model control group, and the fatty vacuolar degeneration of the liver tissue was reduced, indicating that metadoxine had an improvement effect on alcohol-induced zebrafish liver damage; in the L-β-galactoglucan 62.5 and 125 μg / mL concentration groups, the pathological histological examination of the liver of zebrafish showed that the hepatocyte structure was fuzzy and the liver tissue had fatty vacuolar degeneration; in the L-β-galactoglucan 250 μg / mL concentration group, the pathological histological examination of the liver of zebrafish showed that the hepatocyte structure was clearer than that in the model control group, and the fatty vacuolar degeneration of the liver tissue was reduced, indicating that L-β-galactoglucan had an improvement effect on alcohol-induced zebrafish liver damage. Effect test 14 ROS scavenging efficacy evaluation 4dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well. L-β-galactoglucan (concentrations are shown in Table 13) was given in water solution, and the positive control was 1000μg / mL of Zhonghua Dieda Pills. A normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. After 1 day of treatment at 28℃, CM-H2DCFDA was added to each experimental group. Except for the normal control group, all other experimental groups were given anhydrous sodium sulfite in water solution to establish a zebrafish fatigue model. After the anhydrous sodium sulfite was given in water solution, the zebrafish were immediately transferred to a 96-well ELISA plate. After the samples were treated with anhydrous sodium sulfite for a period of time, the ROS fluorescence value of zebrafish in each experimental group was detected by a multifunctional ELISA instrument. The statistical analysis results of this indicator were used to evaluate the ROS scavenging effect of L-β-galactoglucan. The statistical analysis results were expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 13 Evaluation of ROS scavenging efficacy of L-β-galactoglucan (n=10) Compared with the model control group, **p<0.01, ***p<0.001 As shown in Table 13 and FIG. 38 , L-β-galactoglucan has a ROS scavenging effect. Effect Test 15 Evaluation of the effect of promoting ATP synthesis 4dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well. L-β-galactoglucan (concentrations are shown in Table 14) was given in water solution, and the positive control was 1000μg / mL concentration of Zhonghua Dieda Pills. At the same time, a normal control group and a model control group were set up, and the capacity of each well was 3mL. After 1 day of treatment at 28℃, except for the normal control group, all other experimental groups were given anhydrous sodium sulfite in water solution to establish a zebrafish fatigue model. After the samples were treated with anhydrous sodium sulfite for a period of time, 10 zebrafish were randomly selected from each experimental group, and the ATP chemical light value in the zebrafish was detected with an ATP content determination kit. The statistical analysis results of this indicator were used to evaluate the efficacy of L-β-galactoglucan in promoting ATP synthesis. The statistical analysis results were expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 14 Evaluation of the efficacy of L-β-galactoglucan in promoting ATP synthesis (n=10) Compared with the model control group, *p<0.05, **p<0.01, ***p<0.001 As shown in Table 14 and FIG. 39 , L-β-galactoglucan has the effect of promoting ATP synthesis. Effect test 16 Evaluation of the effect of promoting lactic acid metabolism 4dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well. L-β-galactoglucan (concentrations are shown in Table 15) was given in water solution, and the positive control was 1000μg / mL of Zhonghua Dieda Pills. A normal control group and a model control group were set up at the same time, and the volume of each well was 3mL. Three experiments were set up in parallel. After 1 day of treatment at 28℃, all experimental groups except the normal control group were given anhydrous sodium sulfite in water solution to establish a zebrafish fatigue model. After the samples were treated with anhydrous sodium sulfite for a period of time, zebrafish samples were collected according to the instructions of the lactate determination kit, and data were collected using a multifunctional microplate reader to analyze the lactate content in zebrafish in each experimental group. The statistical analysis results of this indicator were used to evaluate the efficacy of L-β-galactoglucan in promoting lactate metabolism. The statistical analysis results were expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 15 Evaluation of the effect of L-β-galactoglucan on promoting lactic acid metabolism (n=3) Compared with the model control group, ***p<0.001 As shown in Table 15 and Figure 40, L-β-galactoglucan has the effect of promoting lactic acid metabolism. Effect trial 17: Regulation of intestinal flora Lactobacillus brevis was labeled with red fluorescence using CM-DiI, and 1×10 8 CFU / mL concentration was fed to 5dpf wild-type AB strain zebrafish to establish a zebrafish intestinal flora (Lactobacillus brevis) model. After culture at 28℃ until 6dpf, Lactobacillus brevis was removed and randomly distributed into 6-well plates, with 30 zebrafish treated in each well. L-β-galactoglucan (concentration shown in Table 16) was given in water, and the positive control was 2000μg / mL concentration of Bacillus subtilis combined live bacteria. At the same time, a model control group was set up with a capacity of 3mL per well. After 6h of treatment at 28℃, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. Data were collected using NIS-Elements D 3.20 advanced image processing software to analyze the fluorescence intensity of intestinal Lactobacillus brevis. The statistical analysis results of this indicator were used to evaluate the efficacy of L-β-galactoglucan in regulating intestinal flora (Lactobacillus brevis). The statistical analysis results were expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 16 Evaluation of the efficacy of L-β-galactoglucan in regulating intestinal flora (n=10) Compared with the model control group, **p<0.01, ***p<0.001 As shown in Table 16 and Figures 41 to 43, L-β-galactoglucan has the effect of increasing the number of Lactobacillus brevis in the intestine. Effect Test 18 Evaluation of the Moisturizing and Hydrating Effect of L-β-Galactoglucan 4dpf melanin allele mutant translucent Albino strain zebrafish were randomly selected in 6-well plates, and 30 zebrafish were treated in each well. L-β-galactoglucan (concentrations are shown in Table 17) was given in water, and urea was 600μg / mL as a positive control. A normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. After 18h of treatment at 28℃, the solution was washed, and except for the normal control group, the rest of the experimental groups were given sodium chloride in water to establish a zebrafish water shortage model. After 6h of treatment at 28℃, 10 zebrafish were randomly selected from each experimental group and placed under a dissecting microscope to take pictures and save the pictures. The NIS-Elements D 3.20 advanced image processing software was used to analyze and collect data, and the tail area of ​​zebrafish was analyzed. The statistical analysis results of this indicator were used to evaluate the hydrating and moisturizing effect of L-β-galactoglucan. The statistical analysis results were expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 17 Evaluation of the moisturizing and hydrating effect of L-β-galactoglucan (n=10) Compared with the model control group, *p<0.05, ***p<0.001 As shown in Table 17 and Figures 44 to 46, L-β-galactoglucan has moisturizing and hydrating effects. Effect Test 19 L-β-galactoglucan inhibits β-galactosidase activity 6hpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well. L-β-galactoglucan (concentrations are shown in Table 18) was given in water, and the positive control catalase concentration was 2000μg / mL. A normal control group and a model control group were set up at the same time, and the volume of each well was 3mL. Except for the normal control group, hydrogen peroxide was given in water to establish a zebrafish aging model in all other groups, and the medium was changed every day during the period. After 6 days of treatment at 28℃, the zebrafish in each experimental group were stained with a cell senescence β-galactosidase staining kit. After staining, 10 zebrafish were randomly selected from each experimental group and photographed under a dissecting microscope. The data were collected using NIS-Elements D 3.20 advanced image processing software to analyze the β-galactosidase staining intensity in zebrafish. The statistical analysis results of this indicator were used to evaluate the efficacy of L-β-galactoglucan in inhibiting β-galactosidase activity. The statistical processing results are expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 18 Evaluation of the efficacy of L-β-galactoglucan in inhibiting β-galactosidase activity (n=10) Compared with the model control group, **p<0.01, ***p<0.001 As shown in Table 18 and Figures 47 to 49, L-β-galactoglucan has the effect of inhibiting β-galactosidase activity. Effect test 20 L-β-galactoglucan increases telomerase activity 6hpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, 30 zebrafish were treated in each well, L-β-galactoglucan (concentrations shown in Table 19) was given in water, and the positive control catalase concentration was 2000μg / mL. A normal control group and a model control group were set up at the same time, and the volume of each well was 3mL. Three experiments were set up in parallel. Except for the normal control group, the remaining groups were given hydrogen peroxide in water to establish a zebrafish aging model, and the medium was changed every day during the period. After 6 days of treatment at 28℃, zebrafish samples were collected according to the instructions of Zebrafish TE Elisa Kit, and data were collected using a multifunctional microplate reader to analyze the telomerase activity in zebrafish in each experimental group. The statistical analysis results of this indicator were used to evaluate the efficacy of L-β-galactoglucan in increasing telomerase activity. The statistical analysis results were expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 19 Effect of L-β-galactoglucan on increasing telomerase activity (n=3) Compared with the model control group, *p<0.05, **p<0.01 As shown in Table 19 and FIG. 50 , L-β-galactoglucan has the effect of increasing telomerase activity. Effect test 21 L-β-galactoglucan increases skin elasticity 4dpf wild-type AB strain zebrafish were randomly selected in 6-well plates, and 30 zebrafish were treated in each well. L-β-galactoglucan (concentrations are shown in Table 20) was given in water, and the positive control verisol collagen was 250μg / mL. A normal control group was set up at the same time, and the volume of each well was 3mL. Three experiments were set up in parallel. After 1 day of treatment at 28℃, the total RNA of each group of zebrafish was extracted using Universal RNA Extraction TL Kit C, and the total RNA concentration and purity were determined using a UV-visible spectrophotometer. 2.00μg of total RNA from zebrafish samples was taken, and 20.0μL cDNA was synthesized according to the instructions of the cDNA first-strand synthesis kit. The expression of β-actin, col1a1a, col1a1b, eln1 and eln2 genes was detected by q-PCR. β-actin was used as an internal reference for gene expression, and the relative RNA expression of col1a1a, col1a1b, eln1 and eln2 genes was calculated. The statistical results were expressed as mean ± SE. SPSS 26.0 software was used for statistical analysis, and p < 0.05 indicated that the difference was statistically significant. At the end of the experiment, zebrafish total RNA was extracted, and the RNA concentration and A260 / A280 ratio were determined by UV-visible spectrophotometer (Table 23). The A260 / A280 ratios were all between 1.8 and 2.2, indicating that the extracted zebrafish total RNA was of good quality and could be used for subsequent q-PCR experiments. The primer sequences are shown in Table 21. Table 20 Total RNA concentration and A260 / A280 ratio (n=3) Table 21 Primer sequence information Table 22 Evaluation of the efficacy of L-β-galactoglucan in increasing skin elasticity (col1a1a and col1a1b) (n=3) Compared with the normal control group, *p<0.05, **p<0.01, ***p<0.001 As shown in Table 22 and Figures 51 to 52 , L-β-galactoglucan has the effect of increasing skin elasticity, which is specifically manifested by upregulating the relative expression levels of col1a1a and col1a1b genes. Effect Test 22 L-β-galactoglucan inhibits melanin recruitment 2dpf transgenic vascular green fluorescent Flk1 strain zebrafish were randomly selected in 6-well plates, and 30 zebrafish were treated in each well. L-β-galactoglucan (concentrations are shown in Table 23) was given in water, and human epidermal growth factor was used as a positive control at a concentration of 7.00 μg / mL. A normal control group and a model control group were set up at the same time, with a capacity of 3 mL per well. Except for the normal control group, all other experimental groups were injected with glacial acetic acid to establish a zebrafish tissue injury model. After 2 days of treatment at 28°C, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. NIS-Elements D 3.20 advanced image processing software was used to analyze and collect data, and the melanin signal intensity at the site of zebrafish tissue injury was analyzed. The statistical analysis results of the above indicators were used to evaluate the efficacy of L-β-galactoglucan in inhibiting melanin recruitment. The statistical analysis results were expressed as mean±SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. Table 23 Evaluation of the efficacy of L-β-galactoglucan in inhibiting melanin recruitment (n=10) Compared with the model control group, *p<0.05, ***p<0.001 As shown in Table 23 and Figures 53 to 55, L-β-galactoglucan has the effect of inhibiting melanin recruitment. Effect Test 23 Study on the Application of L-β-galactoglucan in Weaned Piglets 1. Purpose of the experiment To investigate the effects of L-β-galactoglucan on the growth performance and intestinal health indicators of weaned piglets, and to provide an effective evaluation for the application of L-β-galactoglucan in weaned piglets. 2. Test samples and sources The test sample was crude L-β-galactoglucan (water-soluble, total sugar purity of 62.14%), which was prepared according to the corresponding method in Example 1 and provided by Chengdu Saidike Biotechnology Co., Ltd. 3. Experimental Animals and Design This experiment selected 120 healthy weaned piglets (7.46±1.52kg) of Sanyuan hybrid and randomly divided them into 3 groups, with 8 replicates in each group and 5 pigs in each replicate. The experimental site was Changsha Kelikang Agriculture and Animal Husbandry Technology Co., Ltd. After 3 days of pre-feeding, the formal experiment began, and the experimental period was 42 days. All experimental pigs had free access to food and water, and the pig pens were cleaned and disinfected regularly according to the routine cleaning and disinfection system of the pig farm, and the house was kept clean and dry with a suitable temperature. Other feeding and management procedures were carried out according to the routine of the pig farm. The groups and test formulas are as follows: Table 24 Test Grouping Table 25 Feed formula a The core material of the teaching feed includes 0.1 kg of multivitamins, 0.16 kg of choline, 0.05 kg of antioxidants, 0.05 kg of mildew inhibitors, 0.05 kg of copper pentahydrate, 0.03 kg of manganese monohydrate, 0.03 kg of zinc monohydrate, 0.06 kg of iron monohydrate, 0.001 kg of 1% iodine, 0.001 kg of 1% selenium, 0.001 kg of 1% cobalt, and 0.567 kg of zeolite powder. b The core material of the nursery feed includes 0.1 kg of multivitamins, 0.05 kg of mildew inhibitor, 0.05 kg of copper pentahydrate, 0.03 kg of manganese monohydrate, 0.03 kg of zinc monohydrate, 0.06 kg of iron monohydrate, 0.001 kg of 1% iodine, 0.001 kg of 1% selenium, 0.001 kg of 1% cobalt, and 0.727 kg of zeolite powder. 4. Indicators to be measured and data analysis On the 28th and 42nd day of the test, the pigs were weighed on an empty stomach and the data were recorded. During the test period, the feed intake was recorded every day and the feed-to-meat ratio was calculated. The diarrhea and mortality of the pigs were recorded. The feeding, drinking and growth of the pigs were recorded every day, and adverse reactions were observed and recorded in detail. Diarrhea index = total diarrhea score / (number of test pigs*number of days*number of scores per day) Table 26 Scoring criteria for diarrhea index of piglets 4.1 Blood biochemical indicators On the 42nd day of the experiment, one pig with a weight close to the average weight of the group was selected from each group for slaughter, and blood was collected to test serum biochemical indicators. 4.2 Organ Index On the 42nd day of the experiment, one pig with a weight close to the average weight of the group was selected from each group for slaughter. The liver, spleen and kidney were weighed at slaughter to calculate the relative weight (relative weight = organ weight / slaughter weight). 4.3 Intestinal morphology During slaughter, 2 cm of the intestinal tubes from the middle duodenum, the anterior 1 / 4 of the jejunum, and the middle ileum were taken respectively, the contents were washed, fixed with paraformaldehyde, sliced, and stained with HE. On each slice, a field of view with intact and straight villi was selected, and the villus height and crypt depth of 10 intact villi in the field of view were measured. 4.3 Intestinal digestive enzyme activity, antioxidant capacity and immune factor expression The concentrations or activities of intestinal alkaline phosphatase, malondialdehyde (MDA), total antioxidant capacity (T-AOC), superoxide dismutase (SOD), sIgA and other indicators were detected, and the expressions of intestinal IL-10, TNF-α, IL-6, TGF-β1, MUC2 and ZO1 mRNA were detected. 4.4 Intestinal microbial analysis Ileal 16S microbial sequencing was performed at Beijing Novogene Technology Co., Ltd. 4.5 Data Statistical Analysis The data were preliminarily sorted using Excel, and variance analysis was performed using SAS statistical software (SAS 9.4). The results were expressed as mean ± SD, and P < 0.05 was considered significant. 5. Results and Analysis 5.1 Growth performance The pigs were weighed on an empty stomach on days 28 and 42 of the experiment. The growth performance and diarrhea of ​​the piglets are shown in Table 27. Table 27 Effect of L-β-galactoglucan on body weight of weaned piglets The results showed that compared with the control group and the 600g / t group, the 400g / t dose of L-β-galactoglucan significantly increased the body weight and average daily weight gain of 21-day-old weaned piglets after 42 days of feeding (P<0.05). The feed intake of piglets in the 400g / t and 600g / t groups was significantly higher than that in the control group on the 28th to 42nd day of feeding (P<0.05). The diarrhea index of the 600g / t L-β-galactoglucan group was significantly different from that of the control group and the 400g / t group, indicating that high-dose L-β-galactoglucan has an anti-diarrhea effect. 5.2 Effects of L-β-galactoglucan on blood biochemistry of weaned piglets After blood was collected on the day of slaughter, total protein (TP), albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), urea N (BUN), creatinine (CREA), glucose (GLU), triglycerides (TG), cholesterol (CHOL), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), diamine oxidase (DAO), blood ammonia (NH3L), immunoglobulin G (IGG) and immunoglobulin M (IGM) in the serum of the three groups of piglets were detected. Table 28 Effects of L-β-galactoglucan on blood biochemistry of weaned piglets The results showed that compared with the control group or the 600g / t dosage group, the 400g / t dosage group had a tendency to increase the levels of serum TP, LDH, and IGG (0.05<P<0.1). 5.3 Effects of L-β-galactoglucan on organ weights in weaned piglets Table 29 Effects of L-β-galactoglucan on organ indexes of weaned piglets As shown in Table 29, L-β-galactoglucan had no significant effect on the liver, kidney and spleen indexes of weaned piglets (P>0.05). 5.4 Effects of L-β-galactoglucan on intestinal morphology of weaned piglets As can be seen from the table below, L-β-galactoglucan has no significant effect on the intestinal morphology of piglets. The 600g / t dosage group has a tendency to reduce the ratio of jejunal villus and crypt depth compared with the control group (0.05<P<0.1). Table 30 Effects of L-β-galactoglucan on intestinal morphology of weaned piglets 5.4 Effects of L-β-galactoglucan on intestinal enzyme activities and antioxidant capacity in weaned piglets L-β-galactoglucan had no significant effect on the activity of alkaline phosphatase, T-AOC, MDA and sIgA in the jejunum and ileum of piglets. 600g / t dose of L-β-galactoglucan significantly increased the activity of SOD in the ileum of piglets (P<0.05). Table 31 Effect of L-β-galactoglucan on intestinal T-AOC Table 32 Effect of L-β-galactoglucan on intestinal MDA content Table 33 Effect of L-β-galactoglucan on intestinal alkaline phosphatase activity Table 34 Effect of L-β-galactoglucan on intestinal SOD activity Table 35 Effect of L-β-galactoglucan on intestinal sIgA content 5.6 Effects of L-β-galactoglucan on the gene expression of inflammatory factor pathways in the duodenum and jejunum of weaned piglets As can be seen from the table below, L-β-galactoglucan had no significant effect on the expression of TGF, TNF-α, IL-6, IL-10, ZO1 and MUC2 genes in the duodenum, jejunum and ileum of piglets (P>0.05). Table 36 Effects of L-β-galactoglucan on intestinal cytokines and tight junction proteins 5.7 Detection of intestinal microbial diversity To evaluate the effect of L-β-glucan on colonic microorganisms in weaned piglets, the α and β diversity of the three groups were compared in this study. Based on the OUT, Chao, Shannon and Simpson indices, the addition of L-β-galactoglucan to the diet had no significant effect on the abundance and uniformity of the colonic flora. The main flora in the colon of piglets were Firmicutes and Proteobacteria. The addition of L-β-galactoglucan to the diet reduced the abundance of Firmicutes and increased the abundance of Proteobacteria, but there was no significant difference among the three groups. The top 30 genera in abundance were further selected for comparison. The results showed that the addition of L-β-galactoglucan to the diet reduced the abundance of Ornithinicoccus, Bacillus and Frisingicoccus, and increased the abundance of Lachnoclostridium and Subdoligranulum, which can produce short-chain fatty acids. In addition, the linear discriminant analysis (LDA) effect size (LEfSe) method was used to analyze the intestinal microbial composition. The results showed that there were significant differences in Prevotella_9, Micrococcus, Phascolarctobacterium, and Ornithinicoccus between the 600g / t L-β-galactoglucan group and the control group, and Prevotella_9, Micrococcus, and Phascolarctobacterium were significantly enriched in the L-β-galactoglucan group, while Ornithinicoccus was significantly enriched in the control group. Based on the 16S rRNA sequencing results of KEGG level 3 taxonomy, PICRUSt was used to construct the metagenome. The results showed that there were significant differences in the distribution of functional pathways among the groups, and this study selected differential pathways related to microbial metabolism for analysis. Compared with the control group, the functions of genes related to amino acid metabolism such as alanine, aspartic acid, glutamic acid, glycine, serine, and threonine metabolism in the L-β-galactoglucan group were significantly enhanced, and the functions of genes related to glycolysis, gluconeogenesis, starch, and sucrose metabolism were significantly reduced. Table 37 Effect of L-β-galactoglucan on the diversity of colonic bacterial communities in piglets 6. Experimental conclusion The results of this experiment showed that compared with the negative control group, 400g / t L-β-galactoglucan significantly increased the weight and average daily weight gain of piglets after 42 days of feeding; compared with the control group or 600g / t group, the 400g / t group had a trend of increasing serum TP, LDH, and IGG content (0.05<P<0.1). 600g / t L-β-galactoglucan can significantly reduce the diarrhea rate of weaned piglets and significantly increase the ileal SOD activity of piglets (P<0.05). L-β-galactoglucan had no significant effect on the colonic microbial diversity of piglets, but 600g / t L-β-galactoglucan significantly enriched the abundance of Prevotella 9, Micrococcus, and Phascolarctobacterium and enhanced microbial amino acid metabolism, and reduced the function of energy metabolism-related genes (P<0.05). In summary, the addition of L-β-galactoglucan (400g / t) to the diet can promote the growth of weaned piglets, and its effect may appear around 1.5-2 months, and its possible mechanism of action is through promoting immunity. At the same time, high doses (600g / t) of L-β-galactoglucan affect the metabolism of intestinal microbial flora in piglets and significantly reduce the diarrhea rate of weaned piglets. Effect of effect test 24 on growth performance, palatability and health of dogs my country's pet market is huge. In 2023, the pet consumption market will reach 279.3 billion yuan, and it is increasing year by year. In recent years, problems such as pet obesity, poor coat quality, diarrhea and low immunity have attracted much attention from pet owners. Prebiotics cannot be digested and absorbed by the body, but they can promote the proliferation of intestinal probiotics, thereby improving the health of the body and attract the attention of researchers. Among them, β-glucan, as a high-quality prebiotic, has been widely studied and applied in humans, mice, livestock and poultry. Unlike β-glucan, galactoglucan is a type of heteropolysaccharide, mainly found in the endosperm of plant seeds. Its main chain is composed of glucose and mannose connected by β-1,4 bonds, and the side chain is composed of galactose connected to the hexose residues on the main chain by α-1,6 bonds. Studies have found that galactoglucan has the characteristics of acid and alkali resistance, high salt resistance, high viscosity at low concentrations, and stability within a higher temperature range. Intestinal microorganisms include bacteria, viruses, fungi and protozoa, of which bacteria account for more than 98%. The intestinal flora of dogs and cats is mainly composed of strict anaerobes and facultative anaerobes, mainly composed of Metabacteria, Fusobacteria and Bacteroidetes. The intestinal flora of dogs and cats can convert feed and drugs into microbial metabolites and is considered an important metabolic organ. A balanced intestinal flora can regulate the host immune system through metabolites, protect the host from pathogens and provide nutrients to the host to promote host health. Although studies have shown that β-glucan supplementation has beneficial effects on the health of dogs, the effect of β-galactoglucan supplementation on dogs is still unclear. Therefore, this study used beagles as test animals to evaluate the effects of β-galactoglucan on dog growth performance, apparent nutrient digestibility, palatability, blood routine, blood biochemistry, fecal quality and intestinal flora composition, so as to provide a reference for its application in dog diets. 1 Materials and Methods 1.1 Test materials The test sample was crude L-β-galactoglucan (water-soluble, total sugar purity of 62.14%), which was prepared according to the corresponding method in Example 1 and provided by Chengdu Saidike Biotechnology Co., Ltd. 1.2 Experimental design Thirty-two healthy beagle dogs were randomly divided into four groups, with eight dogs in each group. The dogs were fed at regular times every day. The diet of the control group was prepared according to the standard recommended by NRC (2006). The nutritional level is shown in Table 38. The experimental diet was supplemented with β-galactoglucan (0.25%, 0.5% and 1%) on the basis of the control diet, and the dogs were divided into four groups: (1) control group (n = 8), (2) 0.25% β-galactoglucan group (n = 8), (3) 0.5% β-galactoglucan group (n = 8), (4) 1% β-galactoglucan group (n = 8). The experimental period was 28 days. At the end of the experiment, blood samples, hair samples and feces samples were collected for the determination of blood biochemical indices, microbial flora and digestibility. Table 38 Nutritional level of basic feed 1.3 Measurement indicators and methods 1.3.1 Growth performance and feces quality scoring The weight and daily food intake of the dogs were recorded weekly; the daily feces were scored according to the feces scoring standard, and the number of diarrhea times of the dogs during the test period was recorded. The feces scoring was based on the Carciofi method, that is, 1 point: soft feces without a clear shape; 2 points: soft feces with poor shape; 3 points: soft feces with moist shape; 4 points: good and consistent feces shape; 5 points: good feces shape, hard and dry. On the 28th day of the experiment, the hair on the back of each dog was collected and scored 1, 2, or 3 points based on the brightness, smoothness, and skin condition of the hair. The hair quality score was the sum of the three scores. According to the scoring criteria, refer to Table 39: Table 39 Coat scoring standards 1.3.2 Nutrient Apparent Digestibility On the 25th day of the experiment, all feces were collected for 3 consecutive days, weighed and stored in a -20℃ refrigerator for analysis. The contents of crude protein (GB / T 6432-2018), crude fat (GB / T 6433-2006), crude fiber (GB / T 6434-2006) and crude ash (GB / T 6438-2007) in fecal samples were determined. The formula for calculating the apparent digestibility of nutrients is as follows: Apparent digestibility of a nutrient (%) = 100-[100×(b×c) / (a×d)] In the formula: a is the content of a certain nutrient in the feed; b is the content of a certain nutrient in the feces sample; c is the acid-insoluble ash content in the feed, and d is the acid-insoluble ash content in the feces sample. 1.3.3 Blood biochemistry Venous blood was collected on days 0 and 28 of the experiment, part of which was used for routine blood analysis, and the rest of the serum was separated for blood biochemistry and immunoglobulin testing. Immunoglobulins IgA, IgG, and IgM were measured using Elisa kits. 1.3.4 Composition of intestinal flora use Fecal microbial DNA was extracted using the Soil DNA kit. Universal primers 341F (5'-CCTACGGGRSGCAGCAG-3') and 806R (5'-GGACTACVVGGGTATCTAATC-3') were used for amplification and library construction, and 16S rDNA high-throughput sequencing was performed using the Illumina MiSeq platform. Sequencing services were provided by Shanghai Meiji Biopharmaceutical Technology Co., Ltd. The obtained sequences were clustered into operational taxonomic units (OTUs) based on the principle of similarity ≥ 97%. 1.3.5 Palatability The internationally accepted double-bowl test method was used to record each dog's daily food intake and preferred diet, and the feeding rate was calculated. A feeding rate of 0.5 indicated that there was no difference in preference between the two. The feeding rate calculation formula was: feeding rate (diet A / B) = feed intake (diet A / B) / total feed intake (diet A + diet B). 1.3.6 Data processing and analysis SPSS26.0 software was used to perform one-way analysis of variance on the data, and the results were expressed as "mean ± standard error". P ≤ 0.05 indicated a significant difference, and P > 0.05 indicated an insignificant difference. 2 Results 2.1 Effects of β-galactoglucan on dog growth performance As shown in Table 40, there were no significant differences in stool scores, initial body weight, final body weight and hair scores among the groups; compared with the control group, the weight of dogs in each β-galactoglucan-added group was significantly reduced (P≤0.05), the hair score and stool score of the 0.5% β-galactoglucan group showed an upward trend, and the stool shape was relatively good. Table 40 Effect of β-galactoglucan on growth performance Note: Values ​​are expressed as mean ± standard error, n = 8. Data in the same row without letters or with the same letters indicate no significant difference (P>0.05), and data with different letters indicate significant difference (P≤0.05). 2.2 Effect of β-galactoglucan on apparent digestibility of nutrients in dogs As can be seen from Table 41, after 28 days of experimental treatment, the apparent digestibility of crude fiber in the group with 0.25% β-galactoglucan addition was significantly reduced compared with the control group (P≤0.05); the addition of different levels of β-galactoglucan had no significant effect on the apparent digestibility of crude protein, crude fat and crude ash (P>0.05). Table 41 Effect of β-galactoglucan on apparent digestibility Note: Values ​​are expressed as mean ± standard error, n = 8. Data in the same row without letters or with the same letters indicate no significant difference (P>0.05), and data with different letters indicate significant difference (P≤0.05). 2.3 Effects of β-galactoglucan on routine blood tests in dogs As shown in Table 42, after 28 days of experimental treatment, there were no significant differences in the number of white blood cells, number of red blood cells, hemoglobin content, number of platelets, hematocrit, mean red blood cell volume and mean red blood cell hemoglobin content in each β-galactoglucan addition group compared with the control group (P>0.05). Table 42 Effect of β-galactoglucan on blood routine Note: Values ​​are expressed as mean ± standard error, n = 8. Data in the same row without letters or with the same letters indicate no significant difference (P>0.05), and data with different letters indicate significant difference (P≤0.05). 2.4 Effects of β-galactoglucan on canine serum biochemistry As shown in Table 43, there were no significant differences in blood glucose levels, total protein, albumin, globulin, alanine aminotransferase, blood lipids and high-density lipoprotein levels in the β-galactoglucan-added groups compared with the control group; compared with the control group and the 1% β-galactoglucan group, the low-density lipoprotein content of dogs in the 0.5% β-galactoglucan group was significantly reduced (P≤0.05). Table 43 Effects of β-galactoglucan on blood biochemistry Note: Values ​​are expressed as mean ± standard error, n = 8. Data in the same row without letters or with the same letters indicate no significant difference (P>0.05), and data with different letters indicate significant difference (P≤0.05). 2.5 Effect of β-galactoglucan on canine serum immunoglobulin As shown in Table 44, there was no significant difference in the IgA, IgG and IgM levels in the β-galactoglucan-added groups compared with the control group (P>0.05). Table 44 Effect of β-galactoglucan on serum immunoglobulin Note: Values ​​are expressed as mean ± standard error, n = 8. Data in the same row without letters or with the same letters indicate no significant difference (P>0.05), and data with different letters indicate significant difference (P≤0.05). 2.6 Effect of β-galactoglucan on canine fecal microorganisms Compared with the control group, the α diversity (Chao index) of the microbial community in the 0.5% β-galactoglucan-added group increased significantly (P≤0.05), and the Simpson index decreased significantly (P≤0.05). There was no significant difference in the Shannon index between the control group and each added group. The Venn diagram is used to count the number of common and unique species in multiple groups or samples (Figure 59). As shown in the Venn diagram of fecal flora in Figure 59A, there are 114 common flora in the control group and the experimental group; all four groups have unique intestinal flora, including 4 in the control group, 17 in the 0.25% β-galactoglucan-added group, 22 in the 0.5% β-galactoglucan-added group, and 23 in the 1% β-galactoglucan-added group. As shown in Figure 59B, the fecal microbial β diversity (PCOA analysis) shows that the flora structure of the groups with different concentrations of β-galactoglucan added tends to deviate from the control group. As shown in Figure 59C, at the phylum level, the fecal microbiota is mainly composed of Firmicutes, followed by Actinobacteriota and Bacteroidota; compared with the control group, the relative abundance of Firmicutes in the 0.5% β-galactoglucan addition group showed a downward trend, while the relative abundance of Actinobacteria and Bacteroidetes showed an upward trend. As shown in Figure 59D, at the genus level, the fecal microbiota mainly includes Lactobacillus as the main genus; Peptoclostridium, Blautia, Turicibacter, Romboutsia, unclassified_f_Peptostreptococca and Collinsella, etc. Compared with the control group, the relative abundance of Lactobacillus in the 0.25% β-galactoglucan supplemented group and the 0.5% β-galactoglucan supplemented group showed a downward trend; the relative abundance of Brautia and Bacteroides in the 0.25% β-galactoglucan supplemented group increased significantly (P≤0.05), and the relative abundance of Turicibacter and unclassified_f_Peptostreptococca showed an upward trend. 2.7 Effect of β-galactoglucan on canine palatability As shown in Table 45, different concentrations of β-galactoglucan were selected for palatability comparison. It was found that compared with the control group, the feeding rate of the dogs in the 0.25% β-galactoglucan group was significantly increased (P≤0.05). The feeding amount and first choice rate showed an upward trend. Compared with the 1% β-galactoglucan group, the feeding amount, feeding rate and first choice rate of the dogs in the 0.5% β-galactoglucan group showed an upward trend. The dogs in the 0.5% β-galactoglucan group showed better palatability. Table 45 Effect of β-galactoglucan on palatability Note: Values ​​are expressed as mean ± standard error, n = 8. Data in the same row without letters or with the same letters indicate no significant difference (P>0.05), and data with different letters indicate significant difference (P≤0.05). 3 Discussions 3.1 Effects of β-galactoglucan on dog growth performance The fecal quality, weight change and coat score of pet dogs can easily judge the health status of pet dogs. This experiment explored the effect of β-galactoglucan on the growth performance of dogs. It was found that compared with the control group, the addition of β-galactoglucan had no significant effect on the fecal score and hair score of dogs, and the weight of dogs in each group of β-galactoglucan addition decreased significantly (P≤0.05). Wu et al. found that adding 5.83% oat β-glucan to the diet of 21d weaned piglets instead of corn starch in the diet reduced the average daily feed intake and average daily weight gain of piglets, and the apparent nutrient digestibility of fecal dry matter, crude protein, crude fiber, crude fat and calcium and phosphorus decreased. In addition, Santos et al. found that the addition of dehydrated yeast culture increased the apparent nutrient digestibility of crude fiber in dogs and reduced the digestibility of crude protein and nitrogen-free extract (P<0.05). Another study showed that the addition of oat β-glucan extract showed a trend of reducing the apparent digestibility of crude protein, dry matter and minerals in dogs. Sweeney et al. found that adding 250 mg / kg yeast or seaweed β-glucan to the diet did not affect the growth performance of piglets and the digestibility of dry matter, organic matter and minerals, indicating that adding β-glucan does not change the natural growth pattern of animals and damage animal health. Under the conditions of this experiment, compared with the control group, there was no significant difference in the apparent digestibility of crude protein, crude fat and crude ash in the dogs in the β-galactoglucan-added group, and the apparent digestibility of crude fiber in the dogs in the 0.25% β-galactoglucan-added group was significantly reduced. The possible reason is that β-galactoglucan increases the viscosity of food in the digestive tract and prolongs gastric emptying time, thereby affecting weight changes and apparent digestibility, showing the potential of β-galactoglucan for feeding obese animals. 3.2 Effects of β-galactoglucan on canine blood biochemistry Serum biochemistry and blood routine index tests can directly determine the health status and metabolism of animals. Low-density lipoprotein is a type of apolipoprotein whose main function is to transport cholesterol from the liver to other parts of the body. Low levels of low-density lipoprotein are generally considered a good indicator of health. Under the conditions of this experiment, the low-density lipoprotein content in the 0.5% β-galactoglucan group was significantly lower than that in the control group and the 1% β-galactoglucan group (P≤0.05). This result indicates that dogs in the 0.5% β-galactoglucan group have a lower risk of cardiovascular disease. Ferreira et al.

[0016] The study showed that the serum total cholesterol concentration, low-density lipoprotein and very low-density lipoprotein concentrations of dogs in the 1% oat β-glucan supplementation group were lower than those in the control group (P<0.05). The main immunoglobulins in the blood are IgA, IgM and IgG. Hofer et al. studied the mechanism of immune function and found that glucan can stimulate the proliferation of immune cells and enhance the body's immunity by specifically binding to immune cells in the body. Shao et al. [1] Studies have shown that adding a certain dose of glucan to the diet can increase the serum IgA and IgG levels in broiler chickens. Stuyven et al.

[0019] Studies have shown that after adding yeast β-glucan daily for 4 weeks, the serum IgA level of the dogs in the test group was significantly reduced compared with the control group, and the serum total IgM level was significantly increased, with no effect on the IgG level. The effect disappeared after stopping the supplementation of β-glucan for 1 week. Under the conditions of this experiment, the immunoglobulin content of the dogs in the β-galactoglucan-supplemented group did not change significantly compared with the control group. The possible reason is that β-galactoglucan indirectly affects the overall function of the immune system by activating immune cells, so the direct effect on immunoglobulin production is small. 3.3 Effect of β-galactoglucan on canine palatability Palatability is an important indicator for evaluating pet food. Good palatability of pet food can increase the consumption willingness of pet owners, ensure the pet's food intake and promote the health of the pet. The palatability of pet food is affected by animal factors (such as species, breed, weight, gender), feed factors (such as raw materials, nutrients, feed additives, processing technology), and environmental factors (such as season, temperature, humidity). It mainly affects the pet's enthusiasm for eating and the frequency of eating.

[0020] Under the experimental conditions, compared with the control group, the feed intake rate of the dogs in the 0.25% β-galactoglucan supplementation group increased significantly (P≤0.05), and the feed intake and first choice rate showed an upward trend. Compared with the 1% β-galactoglucan supplementation group, the feed intake, feed intake rate and first choice rate of the dogs in the 0.5% β-galactoglucan supplementation group showed an upward trend. Comprehensive analysis of the experimental results shows that dogs have a better palatability for 0.25% and 0.5% concentrations of β-galactoglucan. 3.4 Effect of β-galactoglucan on canine fecal microorganisms There are many types of intestinal bacteria that coexist with the body and are huge in number, which are vital to the health of the body. The diversity of intestinal flora is often reflected by Alpha diversity and Beta diversity. Alpha diversity is used to evaluate the species richness and diversity in a single sample. The Chao1 index represents the species richness in the sample, and the Simpson index and Shannon index are parameters that reflect species diversity. The larger the value, the higher the degree of diversity. The results of this experiment showed that β-galactoglucan did not change the core flora composition and normal flora structure at the level of canine intestinal microorganisms; at the genus level, compared with the control group, the relative abundance of Brautia and Bacteroides in the 0.25% β-galactoglucan group increased significantly (P≤0.05), and the relative abundance of Turicibacter and unclassified_f_Peptostreptococca showed an upward trend. In summary, β-galactoglucan may promote intestinal health by promoting the proliferation of beneficial bacteria such as Brautia, Bacteroides, and Turicibacter and shaping the acidic intestinal environment, thereby improving the palatability and body health of pets. 4 Conclusion In this experiment, the addition of different concentrations of β-galactoglucan can significantly reduce the weight of dogs, showing the potential of β-galactoglucan for feeding obese animals. β-galactoglucan can improve the palatability of feed. Compared with other groups, dogs in the 0.25% and 0.5% β-galactoglucan addition groups showed better palatability. The addition of β-galactoglucan can reduce the risk of cardiovascular disease. Compared with the control group and the 1% β-galactoglucan group, the low-density lipoprotein content of dogs in the 0.5% β-galactoglucan addition group was significantly reduced (P≤0.05). β-galactoglucan can promote the proliferation of probiotics. Compared with other groups, the relative abundance of beneficial bacteria such as Brautia, Bacteroides, and Geobacter in the 0.25% β-galactoglucan addition group was increased. In addition, the intestinal species richness of dogs in the β-galactoglucan addition group was also improved. β-galactoglucan has application value in pet food, which helps to reduce obesity, improve palatability and the relative abundance of beneficial intestinal bacteria, and improve stool shape and coat quality. The recommended concentration of β-galactoglucan in dog food is 0.25-0.5%. Effect Test 25 on Malassezia Malassezia was cultured in a medium containing malt extract agar, ox bile (dry), Tween 40, glycerol monooleate and chloramphenicol. Malassezia was collected and washed with sterile PBS, and 1×10 7 Then, 1×10 / mL bacterial suspension was prepared by using DMEM to prepare keratinocytes HaCaT in the logarithmic growth phase. 5 / mL cell suspension for later use; 0.1% biopolysaccharide stock solution was prepared with DMEM medium for later use. 2mL HaCaT cell suspension and 1mL DMEM medium were added to the blank control group, mixed thoroughly and inoculated in a 35mm culture dish; 200μL Malassezia suspension, 2mL HaCaT cell suspension and 800μL DMEM medium were taken in the model control group, mixed thoroughly and inoculated in a 35mm culture dish; 0.0039% biopolysaccharide group: 200μL Malassezia suspension, 2mL HaCaT cell suspension, 117μL 0.1% biopolysaccharide stock solution and 683μL DMEM medium were taken, mixed thoroughly and inoculated in a 35mm culture dish; 0.0078% biopolysaccharide group: 200μL Malassezia suspension, 2mL HaCaT cell suspension, 234μL 0.1% biopolysaccharide stock solution and 566μL DMEM medium, mixed thoroughly and inoculated in a 35mm culture dish; 0.0156% biopolysaccharide group: 200μL Malassezia suspension and 2mL HaCaT cell suspension, 468μL 0.1% biopolysaccharide mother solution and 332μL DMEM medium, mixed thoroughly and inoculated in a 35mm culture dish; the cells in the above groups were placed in a 37℃ carbon dioxide incubator and continued to be cultured for 24h. All groups of cells were collected and washed with PBS three times. 1mL Trizol was added to each group of cells to extract RNA; RNA was reverse transcribed into cDNA using a reverse transcription kit; RT-qPCR was then performed using the SYBR Green method to detect the mRNA expression level of the IL-6 gene. Statistical analysis results were expressed as mean ± SEM. GraphPad Prism 8.0 software was used for statistical analysis, and p < 0.05 indicated that the difference was statistically significant. The experimental results are shown in Table 46 and Figure 60. After Malassezia treatment, the relative expression level of IL-6 gene in the model control group cells was 4089.85±424.1%, and the relative expression of IL-6 gene was upregulated by 3989.85% (p<0.001), indicating that the Malassezia-induced IL-6 upregulation inflammation model was successfully constructed (very significant). Under the same conditions, the relative expression of IL-6 gene in cells after treatment with 0.0039%, 0.0078% and 0.0156% biopolysaccharide was 3153.66±281.0%, 1440.53±209.3 and 739.05±44.83%, which were down-regulated by 936.19% (p>0.05), 2649.32% (p<0.001) and 3350.8% (p<0.001) respectively compared with the model control group, indicating that 0.0039%, 0.0078% and 0.0156% biopolysaccharide have the effect of inhibiting the expression of inflammatory factor IL-6 gene induced by Malassezia (very significant). Under the conditions of this experiment, biopolysaccharide has the effect of soothing the scalp. Table 46 Effect of biopolysaccharides on the relative expression level of IL-6 gene in HaCaT cells induced by Malassezia Note: Compared with the blank control group, the model control group: #p<0.05, ##p<0.01, ###p<0.001; compared with the sample group and the model control group: *p<0.05, **p<0.01, ***p<0.001.

Claims

1. An L-β-galactoglucan, characterized in that: Its repeating unit structural formula I is as follows: Wherein, Glcp is glucose, Galp is galactopyranose, and n is an integer not less than 30; Among them, the content of glucose is 94% to 98%, and the content of galactose is 2% to 6%.

2. The L-β-galactoglucan according to claim 1, characterized in that The L-β-galactoglucan is levulose, and the molecular weight is not less than 5000Da.

3. The L-β-galactoglucan according to claim 1, characterized in that The weight average molecular weight is 4.5 million to 5.5 million Da.

4. The method for preparing L-β-galactoglucan according to claim 1, characterized in that: The steps include: (1) inoculating Agrobacterium FN01 into a culture solution for fermentation to obtain a fermentation solution; (2) The fermentation broth is precipitated with alcohol and dried to obtain a crude polysaccharide; the crude polysaccharide is dissolved, an alkali and a filter aid are added to filter, and the filtrate is precipitated with alcohol and dried to obtain a pure polysaccharide; or the fermentation broth is hydrolyzed with glucanase, filtered, concentrated by ultrafiltration, and spray-dried to obtain a pure polysaccharide.

5. A crude L-β-galactoglucan polysaccharide, characterized in that: It is prepared by the following method: comprising the following steps: (1) inoculating Agrobacterium FN01 into a culture solution for fermentation to obtain a fermentation solution; (2) The fermentation liquid is subjected to alcohol precipitation and drying to obtain a crude polysaccharide product.

6. Application of L-β-galactoglucan, Agrobacterium FN01 fermentation broth containing L-β-galactoglucan, and crude L-β-galactoglucan polysaccharide in the preparation of one of the following products: (1) Products for treating and / or preventing diseases related to glucose metabolism disorders; (2) Products that promote skin repair; (3) Products that enhance nonspecific immune function; (4) Products for the treatment and / or prevention of liver damage; (5) Anti-fatigue products; (6) Products that regulate intestinal flora; (7) Anti-aging products; (8) Products that have at least one of the following functions: moisturizing, increasing skin elasticity, and whitening and removing freckles; (9) Products that improve the health of farmed animals; (10) Products that inhibit Malassezia.

7. The use according to claim 6, characterized in that: The product for treating and / or preventing diseases related to glucose metabolism disorders is a product for protecting pancreatic β cells and / or lowering blood sugar.

8. The use according to claim 6, characterized in that: The said enhancing immune function refers to increasing the number of immune cells and / or regulating the function of immune cells.

9. The use according to claim 6, characterized in that: The immune function enhancement refers to products that increase the number of macrophages, neutrophils, and lymphocytes.

10. The use according to claim 6, characterized in that: The liver damage includes alcoholic liver damage and non-alcoholic liver damage.

11. The use according to claim 6, characterized in that: The product for treating and / or preventing liver-related diseases refers to a product that reduces liver transaminase activity and protects liver tissue.

12. The use according to claim 6, characterized in that: The anti-fatigue product refers to a product having at least one of the functions of clearing ROS, promoting ATP synthesis, and promoting lactic acid metabolism.

13. The use according to claim 6, characterized in that: The product for regulating intestinal flora is a product that promotes the proliferation of intestinal probiotics and promotes intestinal health.

14. The use according to claim 6, characterized in that: The anti-aging refers to inhibiting the activity of β-galactosidase and / or increasing the activity of telomerase.

15. The use according to claim 6, characterized in that: The increasing of skin elasticity refers to upregulating the relative expression levels of col1a1a and col1a1b genes.

16. The use according to claim 6, characterized in that: The domesticated animals are selected from livestock and pets; the livestock include pigs, cattle, and sheep; the pets include dogs and cats.

17. The use according to claim 16, characterized in that Improving the health status of livestock refers to one or more of promoting growth, promoting immunity, improving intestinal microbial flora, and reducing diarrhea; improving the health status of pets refers to one or more of reducing obesity, improving palatability, increasing the relative abundance of intestinal probiotics, improving stool shape, and improving coat quality.

18. The use according to claim 17, characterized in that In the method of improving the health of livestock, the dosage of L-β-galactoglucan is 400-600 g / ton of common feed; in the method of improving the health of pets, the percentage of L-β-galactoglucan added in the diet is 0.25-0.5%.

19. The use according to claim 6, characterized in that: The promoting of skin repair includes at least one of promoting tissue regeneration, wound healing, and elimination of apoptotic cells.

20. The use according to claim 6, characterized in that The whitening and freckle removal includes inhibiting melanin.

21. The use according to claim 6, characterized in that: The inhibition of Malassezia refers to the inhibition of the expression of inflammatory factors induced by Malassezia.

22. The use according to claim 6, characterized in that: The product for inhibiting Malassezia is a product for treating skin infections caused by Malassezia.

23. The use according to claim 22, characterized in that The product for inhibiting Malassezia is a product for treating scalp infection induced by Malassezia.

Images